Antigen	O
receptor	O
signaling	O
induces	O
MAP	O
kinase-mediated	O
phosphorylation	O
and	O
degradation	O
of	O
the	O
BCL-6	B-protein
transcription	B-protein
factor	I-protein
.	O

The	O
bcl-6	B-DNA
proto-oncogene	I-DNA
encodes	O
a	O
POZ/zinc	B-protein
finger	I-protein
transcriptional	I-protein
repressor	I-protein
expressed	O
in	O
germinal	B-cell_type
center	I-cell_type
(	I-cell_type
GC	I-cell_type
)	I-cell_type
B	I-cell_type
and	I-cell_type
T	I-cell_type
cells	I-cell_type
and	O
required	O
for	O
GC	O
formation	O
and	O
antibody	O
affinity	O
maturation	O
.	O

Deregulation	O
of	O
bcl-6	B-DNA
expression	O
by	O
chromosomal	O
rearrangements	O
and	O
point	O
mutations	O
of	O
the	O
bcl-6	B-DNA
promoter	I-DNA
region	I-DNA
are	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
B-cell	O
lymphoma	O
.	O

The	O
signals	O
regulating	O
bcl-6	B-DNA
expression	O
are	O
not	O
known	O
.	O

Here	O
we	O
show	O
that	O
antigen	O
receptor	O
activation	O
leads	O
to	O
BCL-6	B-protein
phosphorylation	O
by	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
.	O

Phosphorylation	O
,	O
in	O
turn	O
,	O
targets	O
BCL-6	B-protein
for	O
rapid	O
degradation	O
by	O
the	O
ubiquitin	B-protein
/	O
proteasome	B-protein
pathway	O
.	O

These	O
findings	O
indicate	O
that	O
BCL-6	B-protein
expression	O
is	O
directly	O
controlled	O
by	O
the	O
antigen	O
receptor	O
via	O
MAPK	B-protein
activation	O
.	O

This	O
signaling	O
pathway	O
may	O
be	O
crucial	O
for	O
the	O
control	O
of	O
B-cell	O
differentiation	O
and	O
antibody	O
response	O
and	O
has	O
implications	O
for	O
the	O
regulation	O
of	O
other	O
POZ/zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	O
other	O
tissues	O
.	O

Antigen	NULL
receptor	NULL
signaling	NULL
induces	NULL
MAP	NULL
kinase-mediated	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
the	NULL
BCL-6	NULL
transcription	NULL
factor	NULL
Huifeng	NULL
Niu	NULL
,	NULL
Bihui	NULL
H.	NULL
Ye	NULL
,	NULL
and	NULL
Riccardo	NULL
Dalla-Favera	NULL
'	NULL
Departments	NULL
of	NULL
Pathology	NULL
and	NULL
Genetics	NULL
and	NULL
Development	NULL
,	NULL
Columbia	NULL
University	NULL
,	NULL
New	NULL
York	NULL
,	NULL
New	NULL
York	NULL
10032	NULL
USA	NULL
The	NULL
bel-6	NULL
proto-oncogene	NULL
encodes	NULL
a	NULL
POZ/zinc	NULL
finger	NULL
transcriptional	NULL
repressor	NULL
expressed	NULL
in	NULL
germinal	NULL
center	NULL
(	NULL
GC	NULL
)	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
and	NULL
required	NULL
for	NULL
GC	NULL
formation	NULL
and	NULL
antibody	NULL
affinity	NULL
maturation	NULL
.	NULL

Deregulation	NULL
of	NULL
bel-6	NULL
expression	NULL
by	NULL
chromosomal	NULL
rearrangements	NULL
and	NULL
point	NULL
mutations	NULL
of	NULL
the	NULL
bei-6	NULL
promoter	NULL
region	NULL
are	NULL
implicated	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
B-cell	NULL
lymphoma	NULL
.	NULL

The	NULL
signals	NULL
regulating	NULL
bc/-6	NULL
expression	NULL
are	NULL
not	NULL
known	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
antigen	NULL
receptor	NULL
activation	NULL
leads	NULL
to	NULL
BCL-6	NULL
phosphorylation	NULL
by	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
(	NULL
MAPK	NULL
)	NULL
.	NULL

Phosphorylation	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
targets	NULL
BCL-6	NULL
for	NULL
rapid	NULL
degradation	NULL
by	NULL
the	NULL
ubiquitin/proteasome	NULL
pathway	NULL
.	NULL

These	NULL
findings	NULL
indicate	NULL
that	NULL
BCL-6	NULL
expression	NULL
is	NULL
directly	NULL
controlled	NULL
by	NULL
the	NULL
antigen	NULL
receptor	NULL
via	NULL
MAPK	NULL
activation	NULL
.	NULL

This	NULL
signaling	NULL
pathway	NULL
may	NULL
be	NULL
crucial	NULL
for	NULL
the	NULL
control	NULL
of	NULL
B-cell	NULL
differentiation	NULL
and	NULL
antibody	NULL
response	NULL
and	NULL
has	NULL
im	NULL
plications	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
other	NULL
POZ/zinc	NULL
finger	NULL
transcription	NULL
factors	NULL
in	NULL
other	NULL
tissues	NULL
.	NULL

[	NULL
Key	NULL
Words	NULL
:	NULL
BCL-6	NULL
;	NULL
BCR	NULL
signaling	NULL
;	NULL
MAP	NULL
kinase	NULL
;	NULL
POZ/zinc	NULL
finger	NULL
proteins	NULL
;	NULL
ubiquitin-proteasom	NULL
e	NULL
]	NULL
Received	NULL
March	NULL
12	NULL
,	NULL
1998	NULL
;	NULL
revised	NULL
version	NULL
accepted	NULL
May	NULL
4	NULL
,	NULL
1998	NULL
.	NULL

The	NULL
bel-6	NULL
proto-oncogene	NULL
was	NULL
identified	NULL
by	NULL
virtue	NULL
of	NULL
its	NULL
involvement	NULL
in	NULL
chromosomal	NULL
translocations	NULL
in	NULL
diffuse	NULL
large	NULL
cell	NULL
lymphoma	NULL
(	NULL
DLCL	NULL
)	NULL
,	NULL
the	NULL
most	NULL
common	NULL
form	NULL
of	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
(	NULL
NHL	NULL
)	NULL
(	NULL
Baron	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Kerckaert	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Ye	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Miki	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
)	NULL
.	NULL

Subsequent	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
rearrangements	NULL
of	NULL
the	NULL
bel-6	NULL
gene	NULL
can	NULL
be	NULL
found	NULL
in	NULL
30	NULL
%	NULL
-40	NULL
%	NULL
of	NULL
DLCL	NULL
and	NULL
in	NULL
a	NULL
minority	NULL
(	NULL
5	NULL
%	NULL
-10	NULL
%	NULL
)	NULL
of	NULL
follicular	NULL
lymphoma	NULL
(	NULL
FL	NULL
)	NULL
(	NULL
Bastard	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
LoCoco	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Otsuki	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

These	NULL
rearrangements	NULL
juxtapose	NULL
heterologous	NULL
promoters	NULL
,	NULL
derived	NULL
from	NULL
other	NULL
chromosomes	NULL
,	NULL
to	NULL
the	NULL
bel-6	NULL
coding	NULL
domain	NULL
,	NULL
causing	NULL
its	NULL
deregulated	NULL
expression	NULL
by	NULL
a	NULL
mechanism	NULL
called	NULL
promoter	NULL
substitution	NULL
(	NULL
Ye	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

1998	NULL
)	NULL
.	NULL

The	NULL
5	NULL
'	NULL
noncoding	NULL
region	NULL
of	NULL
the	NULL
bel-6	NULL
gene	NULL
can	NULL
also	NULL
be	NULL
altered	NULL
by	NULL
somatic	NULL
point	NULL
mutations	NULL
that	NULL
are	NULL
detectable	NULL
,	NULL
independent	NULL
of	NULL
re-arrangements	NULL
,	NULL
in	NULL
~70	NULL
%	NULL
DLCL	NULL
,	NULL
45	NULL
%	NULL
FL	NULL
,	NULL
and	NULL
AIDS-asso-ciated	NULL
NHL	NULL
(	NULL
Migliazza	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Gaidano	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
rearrangements	NULL
and	NULL
mutations	NULL
of	NULL
the	NULL
bel-6	NULL
promoter	NULL
region	NULL
represent	NULL
the	NULL
most	NULL
frequent	NULL
genetic	NULL
alteration	NULL
in	NULL
human	NULL
B-cell	NULL
malignancies	NULL
,	NULL
suggesting	NULL
they	NULL
may	NULL
be	NULL
important	NULL
for	NULL
tumorigenesis	NULL
(	NULL
Dalla-Fa-vera	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

The	NULL
BCL-6	NULL
protein	NULL
is	NULL
a	NULL
nuclear	NULL
phosphoprotein	NULL
belonging	NULL
to	NULL
the	NULL
POZ/zinc	NULL
finger	NULL
(	NULL
ZF	NULL
)	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
Kerckaert	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Ye	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Miki	NULL
et	NULL
al	NULL
.	NULL

*Corresponding	NULL
author	NULL
.	NULL

E-MAIL	NULL
RD10	NULL
@	NULL
columbia.edu	NULL
;	NULL
FAX	NULL
(	NULL
212	NULL
)	NULL
305-5498	NULL
.	NULL

1994	NULL
)	NULL
.	NULL

It	NULL
contains	NULL
six	NULL
Kmippel-type	NULL
carboxy-terminal	NULL
zinc	NULL
finger	NULL
(	NULL
ZF	NULL
)	NULL
motifs	NULL
that	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
recognize	NULL
specific	NULL
DN	NULL
A	NULL
sequences	NULL
in	NULL
vitro	NULL
(	NULL
Chang	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Seyfert	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
and	NULL
an	NULL
amino-terminal	NULL
POZ	NULL
motif	NULL
(	NULL
Al-bagli	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
shared	NULL
by	NULL
various	NULL
ZF	NULL
molecules	NULL
including	NULL
the	NULL
Drosophila	NULL
developmental	NULL
regulators	NULL
Tram	NULL
track	NULL
and	NULL
Broad-com	NULL
plex	NULL
(	NULL
Harrison	NULL
and	NULL
Travers	NULL
1990	NULL
;	NULL
DiBello	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
)	NULL
,	NULL
the	NULL
human	NULL
KUP	NULL
(	NULL
Chardin	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
)	NULL
,	NULL
ZID	NULL
(	NULL
Bardwell	NULL
and	NULL
Treisman	NULL
1994	NULL
)	NULL
,	NULL
and	NULL
PLZF	NULL
(	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
)	NULL
proteins	NULL
as	NULL
well	NULL
as	NULL
by	NULL
POX	NULL
viruses	NULL
(	NULL
Koonin	NULL
et	NULL
al	NULL
.	NULL

1992	NULL
)	NULL
and	NULL
the	NULL
actin-binding	NULL
Drosophila	NULL
oocyte	NULL
protein	NULL
Keich	NULL
(	NULL
Xue	NULL
and	NULL
Cooley	NULL
1993	NULL
)	NULL
.	NULL

BCL-6	NULL
functions	NULL
as	NULL
a	NULL
potent	NULL
transcriptional	NULL
repressor	NULL
by	NULL
binding	NULL
to	NULL
its	NULL
DN	NULL
A	NULL
target	NULL
sequence	NULL
(	NULL
Deweindt	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Chang	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Seyfert	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

BCL-6	NULL
is	NULL
an	NULL
important	NULL
regulator	NULL
of	NULL
lymphoid	NULL
development	NULL
and	NULL
function	NULL
.	NULL

In	NULL
the	NULL
B-cell	NULL
lineage	NULL
,	NULL
the	NULL
BCL-6	NULL
protein	NULL
is	NULL
found	NULL
only	NULL
in	NULL
B	NULL
cells	NULL
within	NULL
germinal	NULL
centers	NULL
(	NULL
GC	NULL
)	NULL
,	NULL
but	NULL
not	NULL
in	NULL
pre-B	NULL
cells	NULL
or	NULL
in	NULL
differentiated	NULL
progeny	NULL
such	NULL
as	NULL
plasm	NULL
a	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
T-cell	NULL
lineage	NULL
,	NULL
BCL-6	NULL
protein	NULL
is	NULL
detectable	NULL
in	NULL
cortical	NULL
thymocytes	NULL
and	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
within	NULL
GC	NULL
as	NULL
well	NULL
as	NULL
scattered	NULL
in	NULL
the	NULL
perifollicular	NULL
area	NULL
(	NULL
Cattoretti	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Onizuka	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Allman	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Mice	NULL
deficient	NULL
in	NULL
BCL-6	NULL
display	NULL
normal	NULL
B-cell	NULL
,	NULL
T-cell	NULL
,	NULL
and	NULL
lymphoid	NULL
organ	NULL
development	NULL
but	NULL
have	NULL
a	NULL
selective	NULL
defect	NULL
in	NULL
T-cell-dependent	NULL
antibody	NULL
responses	NULL
because	NULL
of	NULL
the	NULL
inability	NULL
of	NULL
follicular	NULL
B	NULL
cells	NULL
to	NULL
proliferate	NULL
and	NULL
form	NULL
GC	NULL
(	NULL
Dent	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
;	NULL
Ye	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
BCL-6-deficient	NULL
mice	NULL
develop	NULL
an	NULL
inflammatory	NULL
re	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
12:1953-1961	NULL
©	NULL
1998	NULL
by	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
ISSN	NULL
0890-9369/98	NULL
$	NULL
5.00	NULL
;	NULL
www.genesdev.org	NULL
1953	NULL
Niu	NULL
et	NULL
al	NULL
.	NULL

sponse	NULL
in	NULL
multiple	NULL
organs	NULL
characterized	NULL
by	NULL
infiltration	NULL
of	NULL
eosinophils	NULL
and	NULL
IgE-bearing	NULL
B	NULL
lymphocytes	NULL
typical	NULL
of	NULL
a	NULL
Th2-mediated	NULL
inflammatory	NULL
response	NULL
.	NULL

These	NULL
pheno-types	NULL
may	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
BCL-6	NULL
to	NULL
bind	NULL
the	NULL
STAT-6	NULL
DNA-binding	NULL
site	NULL
and	NULL
repress	NULL
transcription	NULL
activated	NULL
by	NULL
STAT-6	NULL
,	NULL
the	NULL
main	NULL
nuclear	NULL
effector	NULL
of	NULL
IL-4	NULL
signaling	NULL
(	NULL
Dent	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
;	NULL
Ye	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
and	NULL
requirement	NULL
of	NULL
BCL-6	NULL
during	NULL
GC	NULL
formation	NULL
and	NULL
its	NULL
alteration	NULL
in	NULL
GC-derived	NULL
lymphoma	NULL
suggest	NULL
that	NULL
BCL-6	NULL
may	NULL
be	NULL
a	NULL
key	NULL
regulator	NULL
of	NULL
GC	NULL
development	NULL
and	NULL
antibody-mediated	NULL
immune	NULL
response	NULL
.	NULL

Toward	NULL
the	NULL
elucidation	NULL
of	NULL
the	NULL
signals	NULL
that	NULL
regulate	NULL
GC	NULL
expression	NULL
,	NULL
we	NULL
report	NULL
here	NULL
the	NULL
identification	NULL
of	NULL
a	NULL
signaling	NULL
pathway	NULL
by	NULL
which	NULL
B-cell	NULL
antigen	NULL
receptor	NULL
directly	NULL
regulates	NULL
BCL-6	NULL
stability	NULL
.	NULL

Results	NULL
Recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
BCL-6	NULL
protein	NULL
is	NULL
phosphorylated	NULL
at	NULL
multiple	NULL
sites	NULL
by	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
(	NULL
MAPKs	NULL
)	NULL
,	NULL
ERK-1	NULL
and	NULL
ERK-2	NULL
,	NULL
but	NULL
not	NULL
by	NULL
Jun	NULL
amino-terminal	NULL
kinase	NULL
(	NULL
JNK	NULL
)	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
Moriyama	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
confirm	NULL
that	NULL
purified	NULL
recombinant	NULL
MAPK	NULL
(	NULL
ERK-2	NULL
)	NULL
can	NULL
phosphorylate	NULL
GST-BCL-6	NULL
fusion	NULL
proteins	NULL
in	NULL
vitro	NULL
.	NULL

The	NULL
phosphorylation	NULL
targets	NULL
were	NULL
mapped	NULL
to	NULL
the	NULL
amino-terminal	NULL
half	NULL
of	NULL
the	NULL
molecule	NULL
since	NULL
a	NULL
carboxy-terminal	NULL
deletion	NULL
mutant	NULL
(	NULL
GST	NULL
-BCL-6AZF	NULL
)	NULL
could	NULL
be	NULL
phosphorylated	NULL
at	NULL
levels	NULL
comparable	NULL
to	NULL
the	NULL
wild-type	NULL
molecule	NULL
,	NULL
whereas	NULL
an	NULL
amino-terminal	NULL
deletion	NULL
mutant	NULL
(	NULL
GST-BCL-6ZF	NULL
)	NULL
could	NULL
not	NULL
be	NULL
phosphorylated	NULL
at	NULL
all	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
Because	NULL
BCL-6	NULL
contains	NULL
two	NULL
perfect	NULL
consensus	NULL
sites	NULL
(	NULL
PXSP	NULL
)	NULL
for	NULL
MAPK-mediated	NULL
phosphorylation	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
,	NULL
we	NULL
generated	NULL
two	NULL
mutants	NULL
(	NULL
BCL-6a1,533	NULL
and	NULL
BCL-6a12333,343	NULL
)	NULL
iN	NULL
which	NULL
one	NULL
or	NULL
both	NULL
of	NULL
these	NULL
sites	NULL
were	NULL
altered	NULL
by	NULL
substituting	NULL
serines	NULL
with	NULL
alanines	NULL
.	NULL

These	NULL
two	NULL
mutants	NULL
were	NULL
phosphorylated	NULL
at	NULL
much	NULL
lower	NULL
levels	NULL
than	NULL
wild-type	NULL
BCL-6	NULL
,	NULL
with	NULL
BCL-6a1,533,343	NULL
displaying	NULL
the	NULL
lowest	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

This	NULL
result	NULL
indicates	NULL
that	NULL
the	NULL
Sers	NULL
;	NULL
,	NULL
and	NULL
Serg,4	NULL
;	NULL
residues	NULL
represent	NULL
a	NULL
significant	NULL
fraction	NULL
,	NULL
although	NULL
not	NULL
all	NULL
,	NULL
of	NULL
the	NULL
BCL-6	NULL
phosphorylation	NULL
target	NULL
sites	NULL
.	NULL

The	NULL
residual	NULL
low	NULL
level	NULL
of	NULL
phosphorylation	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
existence	NULL
of	NULL
additional	NULL
potential	NULL
MAPK	NULL
target	NULL
sequences	NULL
(	NULL
SP	NULL
)	NULL
clustered	NULL
within	NULL
the	NULL
central	NULL
domain	NULL
of	NULL
the	NULL
BCL-6	NULL
molecule	NULL
.	NULL

MA	NULL
PK-m	NULL
ediated	NULL
phosphorylation	NULL
induces	NULL
BCL-6	NULL
degradation	NULL
To	NULL
determine	NULL
the	NULL
effects	NULL
of	NULL
MAPK-mediated	NULL
phosphorylation	NULL
on	NULL
be/-6	NULL
expression	NULL
and	NULL
function	NULL
,	NULL
293T	NULL
cells	NULL
(	NULL
which	NULL
do	NULL
not	NULL
express	NULL
endogenous	NULL
BCL-6	NULL
)	NULL
were	NULL
cotransfected	NULL
with	NULL
vectors	NULL
expressing	NULL
BCL-6	NULL
,	NULL
and	NULL
a	NULL
MEK	NULL
(	NULL
MAP/	NULL
ERK	NULL
kinase	NULL
)	NULL
mutant	NULL
(	NULL
MEK-2E	NULL
)	NULL
that	NULL
functions	NULL
as	NULL
a	NULL
constitutively	NULL
active	NULL
MAPK	NULL
kinase	NULL
(	NULL
Yan	NULL
and	NULL
Templeton	NULL
1994	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
transfected	NULL
cell	NULL
extracts	NULL
showed	NULL
that	NULL
MEK-2E	NULL
expression	NULL
(	NULL
documented	NULL
by	NULL
increased	NULL
ERK2	NULL
kinase	NULL
activity	NULL
of	NULL
MEK-2E	NULL
transfected	NULL
cell	NULL
extracts	NULL
in	NULL
solid-phase	NULL
kinase	NULL
assays	NULL
in	NULL
vitro	NULL
;	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
bottom	NULL
)	NULL
induced	NULL
a	NULL
dramatic	NULL
reduction	NULL
of	NULL
BCL-6	NULL
,	NULL
but	NULL
not	NULL
ERK	NULL
,	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
top	NULL
and	NULL
middle	NULL
)	NULL
.	NULL

The	NULL
observed	NULL
reduction	NULL
in	NULL
BCL-6	NULL
protein	NULL
levels	NULL
was	NULL
dependent	NULL
upon	NULL
the	NULL
phosphorylation	NULL
activity	NULL
of	NULL
MEK-2E	NULL
,	NULL
since	NULL
it	NULL
did	NULL
not	NULL
occur	NULL
when	NULL
a	NULL
vector	NULL
expressing	NULL
inactive	NULL
MEK	NULL
was	NULL
cotransfected	NULL
with	NULL
bel-6	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
the	NULL
same	NULL
transfected	NULL
cells	NULL
showed	NULL
that	NULL
the	NULL
reduction	NULL
in	NULL
BCL-6	NULL
protein	NULL
levels	NULL
were	NULL
not	NULL
caused	NULL
by	NULL
decreased	NULL
bel-6	NULL
m	NULL
RN	NULL
A	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
bottom	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
MEK-2E-induced	NULL
decrease	NULL
in	NULL
BCL-6	NULL
levels	NULL
was	NULL
dependent	NULL
on	NULL
target	NULL
phosphorylation	NULL
,	NULL
as	NULL
the	NULL
partial	NULL
phosphorylation-resistant	NULL
mutant	NULL
BCL-6a	NULL
;	NULL
,	NULL
;	NULL
33,343	NULL
Was	NULL
partially	NULL
resistant	NULL
to	NULL
MEK-2E-mediated	NULL
down-regulation	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
MEK-2E-induced	NULL
decrease	NULL
in	NULL
BCL-6	NULL
levels	NULL
is	NULL
not	NULL
caused	NULL
by	NULL
decreased	NULL
gene	NULL
transcription	NULL
or	NULL
protein	NULL
synthesis	NULL
,	NULL
but	NULL
rather	NULL
by	NULL
decreased	NULL
protein	NULL
stability	NULL
.	NULL

A	NULL
ser	NULL
1	NULL
121	NULL
239	NULL
33	NULL
``	NULL
706	NULL
stBe	NULL
-=	NULL
--	NULL
pIIIIIZIZA	NULL
compotion	NULL
1	NULL
GsT-EcLs	NULL
h	NULL
oe	NULL
ngs	NULL
-	NULL
re	NULL
GST-BCLEAF	NULL
-~	NULL
1	NULL
POZ	NULL
steez	NULL
__	NULL
_s	NULL
frm	NULL
,	NULL
Figure	NULL
1	NULL
.	NULL

Phosphorylation	NULL
of	NULL
BCL-6	NULL
by	NULL
5	NULL
ERK2	NULL
in	NULL
vitro	NULL
:	NULL
(	NULL
4	NULL
)	NULL
Schematic	NULL
representa-	NULL
8	NULL
C	NULL
E	NULL
tion	NULL
of	NULL
wild-type	NULL
and	NULL
mutant	NULL
GST-BCL-6	NULL
E	NULL
=	NULL
E	NULL
fusion	NULL
proteins	NULL
.	NULL

(	NULL
*	NULL
)	NULL
Serines	NULL
within	NULL
MAPK	NULL
é	NULL
E-phosphorylation	NULL
sites	NULL
(	NULL
PXSP	NULL
)	NULL
(	NULL
ZF	NULL
)	NULL
Zinc	NULL
;	NULL
E	NULL
$	NULL
7.4	NULL
>	NULL
-finger	NULL
domain	NULL
.	NULL

(	NULL
B	NULL
)	NULL
ERK2	NULL
kinase	NULL
assays	NULL
us-	NULL
C	NULL
sa	NULL
un-	NULL
.-	NULL
<	NULL
-	NULL
GST-BCLEAZF	NULL
ing	NULL
GST-BCL-6	NULL
wild-type	NULL
and	NULL
deletion	NULL
b	NULL
**	NULL
.	NULL

_	NULL
.	NULL

«	NULL
£	NULL
GST-ECLE	NULL
mutants	NULL
as	NULL
substrates	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
37.4	NULL
(	NULL
i	NULL
.	NULL

<	NULL
€EGSTECLGNZF	NULL
(	NULL
C	NULL
)	NULL
(	NULL
Top	NULL
)	NULL
ERK2	NULL
kinase	NULL
assay	NULL
ia	NULL
M	NULL
a	NULL
wa	NULL
io	NULL
for	NULL
wild-type	NULL
(	NULL
WT	NULL
)	NULL
or	NULL
mutant	NULL
(	NULL
Ala333	NULL
;	NULL
smp	NULL
Ala333,343	NULL
)	NULL
GST-BCL6AZEF	NULL
proteins	NULL
.	NULL

(	NULL
Bottom	NULL
)	NULL
Coomassie	NULL
blue	NULL
staining	NULL
of	NULL
the	NULL
gel	NULL
shown	NULL
at	NULL
fop	NULL
demonstrating	NULL
comparable	NULL
amounts	NULL
of	NULL
proteins	NULL
loaded	NULL
.	NULL

Molecular	NULL
mass	NULL
markers	NULL
are	NULL
shown	NULL
at	NULL
leff	NULL
.	NULL

1954	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
«	NULL
C-	NULL
GST-BCLEAZF	NULL
Regulation	NULL
of	NULL
BCL-6	NULL
by	NULL
antigen	NULL
receptor	NULL
signaling	NULL
C	NULL
MEK-2€	NULL
<	NULL
0	NULL
400440	NULL
~	NULL
0	NULL
4	NULL
o	NULL
++	NULL
Bl	NULL
fam	NULL
:	NULL
34s	NULL
-	NULL
~	NULL
no	NULL
¥	NULL
0	NULL
+00	NULL
+	NULL
#	NULL
A.	NULL
MEK-3E	NULL
-~	NULL
0	NULL
+	NULL
+	NULL
#	NULL
00	NULL
ko	NULL
4	NULL
~	NULL
o	NULL
>	NULL
»	NULL
BCL-6	NULL
+	NULL
-	NULL
+	NULL
i	NULL
mae	NULL
]	NULL
SCL-6	NULL
100	NULL
%	NULL
SU	NULL
%	NULL
4	NULL
u	NULL
chat	NULL
Aah	NULL
auth	NULL
<	NULL
-	NULL
C52	NULL
Bo	NULL
30	NULL
40	NULL
506	NULL
f	NULL
D	NULL
``	NULL
ems	NULL
:	NULL
>	NULL
3	NULL
homes	NULL
:	NULL
4	NULL
$	NULL
#	NULL
E	NULL
3	NULL
Zl—E—	NULL
B	NULL
E	NULL
MEX	NULL
mo	NULL
e	NULL
ee	NULL
n	NULL
t	NULL
44	NULL
+44	NULL
€	NULL
MEX-BE	NULL
>	NULL
0-0	NULL
40	NULL
4+	NULL
#	NULL
44	NULL
-	NULL
>	NULL
BCL4	NULL
mo	NULL
todo	NULL
$	NULL
o	NULL
ogo	NULL
4	NULL
4	NULL
KB	NULL
--	NULL
Wout	NULL
-	NULL
met	NULL
(	NULL
BB	NULL
-BCL-G	NULL
Protsin	NULL
BeES-TK-Luc	NULL
t	NULL
t	NULL
t	NULL
t	NULL
t	NULL
+	NULL
to	NULL
&	NULL
#	NULL
t	NULL
4	NULL
%	NULL
&	NULL
+	NULL
+	NULL
BCL4	NULL
604	NULL
$	NULL
$	NULL
#	NULL
®	NULL
op	NULL
&	NULL
)	NULL
o	NULL
>	NULL
k	NULL
>	NULL
>	NULL
>	NULL
>	NULL
0	NULL
Ea	NULL
;	NULL
bray	NULL
n	NULL
n	NULL
n	NULL
n	NULL
t	NULL
t	NULL
t	NULL
t	NULL
ton	NULL
t	NULL
t	NULL
f	NULL
E-BCLS	NULL
mANA	NULL
CLL	NULL
CEP	NULL
20	NULL
__	NULL
e	NULL
10	NULL
20	NULL
%	NULL
0	NULL
40	NULL
5006007	NULL
MEK	NULL
r	NULL
--	NULL
e	NULL
Figure	NULL
2	NULL
.	NULL

BCL-6	NULL
protein	NULL
degradation	NULL
induced	NULL
by	NULL
overexpression	NULL
of	NULL
MEK-2E	NULL
in	NULL
293T	NULL
cells	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
293T	NULL
cells	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
BCL-6	NULL
(	NULL
lanes	NULL
1,3	NULL
)	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
MEK-2E	NULL
(	NULL
lanes	NULL
2,3	NULL
)	NULL
using	NULL
anti-BCL-6	NULL
(	NULL
N-70-6	NULL
;	NULL
top	NULL
)	NULL
or	NULL
anti-ERK2	NULL
(	NULL
C-14	NULL
;	NULL
middle	NULL
)	NULL
antibodies	NULL
.	NULL

(	NULL
Bottom	NULL
)	NULL
The	NULL
results	NULL
of	NULL
solid-phase	NULL
ERK2	NULL
kinase	NULL
assay	NULL
performed	NULL
on	NULL
cell	NULL
extract	NULL
from	NULL
the	NULL
same	NULL
transfectants	NULL
used	NULL
in	NULL
the	NULL
top	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Western	NULL
blot	NULL
(	NULL
fop	NULL
)	NULL
and	NULL
Northern	NULL
blot	NULL
(	NULL
bottom	NULL
)	NULL
analysis	NULL
of	NULL
BCL-6	NULL
in	NULL
293T	NULL
cells	NULL
transfected	NULL
with	NULL
pMT2T-BCL-6	NULL
(	NULL
BCL-6	NULL
)	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
(	NULL
lanes	NULL
1-7	NULL
)	NULL
and	NULL
various	NULL
amounts	NULL
of	NULL
MEK-2E-CMV	NULL
(	NULL
MEK-2E	NULL
)	NULL
(	NULL
lanes	NULL
2-4	NULL
)	NULL
or	NULL
MEK-CMV	NULL
(	NULL
MEK	NULL
)	NULL
(	NULL
5	NULL
,	NULL
10	NULL
,	NULL
or	NULL
15	NULL
ug	NULL
)	NULL
(	NULL
lanes	NULL
5-7	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
293T	NULL
cell	NULL
extracts	NULL
transfected	NULL
with	NULL
wild-type	NULL
BCL-6	NULL
(	NULL
lanes	NULL
1-3	NULL
)	NULL
or	NULL
BCL-6a1,533,343	NULL
(	NULL
lanes	NULL
4-6	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1,4	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lanes	NULL
2,3,5,6	NULL
)	NULL
of	NULL
cotransfected	NULL
MEK-2E	NULL
.	NULL

(	NULL
Bottom	NULL
)	NULL
The	NULL
results	NULL
of	NULL
densitometric	NULL
scanning	NULL
of	NULL
the	NULL
autoradiography	NULL
;	NULL
analogous	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Analysis	NULL
of	NULL
BCL-6	NULL
transrepression	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
active	NULL
MEK	NULL
.	NULL

293T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
2.0	NULL
pmole	NULL
of	NULL
B6BS-TK-Luc	NULL
,	NULL
0.04	NULL
pmole	NULL
of	NULL
pMT2T-BCL-6	NULL
(	NULL
lanes	NULL
2-8	NULL
)	NULL
or	NULL
pMT2T-BCL-	NULL
(	NULL
Lanes	NULL
11-14	NULL
)	NULL
and	NULL
increasing	NULL
amounts	NULL
(	NULL
0.1	NULL
,	NULL
0.2	NULL
,	NULL
0.4	NULL
,	NULL
0.4	NULL
pmole	NULL
)	NULL
of	NULL
MEK-2E	NULL
(	NULL
lanes	NULL
3-5,9,12-14	NULL
)	NULL
or	NULL
MEK	NULL
(	NULL
lanes	NULL
6-8,10	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
48	NULL
hr	NULL
after	NULL
transfection	NULL
and	NULL
luciferase	NULL
activities	NULL
were	NULL
measured	NULL
by	NULL
a	NULL
luminometer	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
MEK-2E-induced	NULL
reduction	NULL
in	NULL
BCL-6	NULL
levels	NULL
,	NULL
a	NULL
transient	NULL
cotransfection	NULL
assay	NULL
in	NULL
293T	NULL
cells	NULL
showed	NULL
that	NULL
MEK-2E	NULL
,	NULL
but	NULL
not	NULL
MEK	NULL
,	NULL
could	NULL
eliminate	NULL
the	NULL
transcriptional	NULL
transrepressor	NULL
activity	NULL
of	NULL
wild-type	NULL
BCL-6	NULL
(	NULL
Fig	NULL
.	NULL

2D	NULL
,	NULL
lanes	NULL
3-5	NULL
)	NULL
on	NULL
a	NULL
reporter	NULL
vector	NULL
expressing	NULL
the	NULL
luciferase	NULL
gene	NULL
downstream	NULL
to	NULL
the	NULL
BCL-6	NULL
DNA-binding	NULL
site	NULL
(	NULL
B6BS	NULL
)	NULL
(	NULL
Chang	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
;	NULL
the	NULL
partial	NULL
phosphorylation-resistant	NULL
mutant	NULL
BCL-6a1,333,343	NULL
WAS	NULL
partially	NULL
resistant	NULL
to	NULL
MEK-2E	NULL
(	NULL
Fig	NULL
.	NULL

2D	NULL
,	NULL
lanes	NULL
12-14	NULL
)	NULL
.	NULL

Overall	NULL
,	NULL
these	NULL
results	NULL
indicate	NULL
that	NULL
MAPK	NULL
activation	NULL
leads	NULL
to	NULL
functional	NULL
inactivation	NULL
of	NULL
BCL-6	NULL
by	NULL
causing	NULL
its	NULL
accelerated	NULL
degradation	NULL
.	NULL

BCL-6	NULL
degradation	NULL
is	NULL
mediated	NULL
by	NULL
ubiquitin/	NULL
proteasome	NULL
pathw	NULL
ay	NULL
In	NULL
examining	NULL
the	NULL
possible	NULL
mechanisms	NULL
for	NULL
MAPK-mediated	NULL
degradation	NULL
of	NULL
BCL-6	NULL
,	NULL
we	NULL
noted	NULL
that	NULL
the	NULL
cluster	NULL
of	NULL
MAPK	NULL
putative	NULL
phosphorylation	NULL
sites	NULL
are	NULL
em	NULL
bedded	NULL
in	NULL
a	NULL
region	NULL
enriched	NULL
in	NULL
proline	NULL
,	NULL
glutamine	NULL
,	NULL
and	NULL
serine	NULL
,	NULL
within	NULL
which	NULL
we	NULL
identified	NULL
three	NULL
typical	NULL
PEST	NULL
sequences	NULL
that	NULL
score	NULL
9.4	NULL
,	NULL
5.0	NULL
,	NULL
and	NULL
2.6	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
;	NULL
any	NULL
score	NULL
above	NULL
zero	NULL
denotes	NULL
a	NULL
possible	NULL
PEST	NULL
region	NULL
;	NULL
scores	NULL
greater	NULL
than	NULL
five	NULL
indicate	NULL
the	NULL
strongest	NULL
candidates	NULL
)	NULL
.	NULL

These	NULL
motifs	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
represent	NULL
targets	NULL
for	NULL
regulated	NULL
protein	NULL
degradation	NULL
(	NULL
Rogers	NULL
et	NULL
al	NULL
.	NULL

1986	NULL
;	NULL
Rechsteiner	NULL
and	NULL
Rogers	NULL
1996	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
MAPK-mediated	NULL
BCL-6	NULL
degradation	NULL
targeted	NULL
these	NULL
PEST	NULL
sequences	NULL
,	NULL
we	NULL
constructed	NULL
vectors	NULL
expressing	NULL
two	NULL
epitope	NULL
HA-tagged	NULL
bel-6	NULL
deletion	NULL
mutants	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
and	NULL
cotransfected	NULL
them	NULL
with	NULL
the	NULL
MEK-2E	NULL
vector	NULL
into	NULL
293T	NULL
cells	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
using	NULL
anti-HA	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
showed	NULL
that	NULL
MEK-2E-mediated	NULL
degradation	NULL
targeted	NULL
the	NULL
amino-terminal	NULL
half	NULL
of	NULL
the	NULL
molecule	NULL
and	NULL
it	NULL
was	NULL
completely	NULL
abolished	NULL
in	NULL
the	NULL
BCL-6A	NULL
@	NULL
300-417	NULL
)	NULL
internal	NULL
deletion	NULL
mutant	NULL
that	NULL
lacks	NULL
a	NULL
small	NULL
portion	NULL
of	NULL
the	NULL
BCL-6	NULL
pro	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
1955	NULL
Niu	NULL
et	NULL
al	NULL
.	NULL

A.	NULL
HA-BCL-6	NULL
1	NULL
HA	NULL
HA-BCLGZF	NULL
418	NULL
Figure	NULL
3	NULL
.	NULL

BCL-6	NULL
contains	NULL
PEST	NULL
sequences	NULL
121	NULL
--	NULL
KFZZZZZZZZ	NULL
]	NULL
POZ	NULL
335i	NULL
'	NULL
3-1-E	NULL
'	NULL
336	NULL
$	NULL
5	NULL
406	NULL
ic	NULL
lar	NULL
PEST	NULL
PEST	NULL
PEST	NULL
6e1	NULL
706	NULL
--	NULL
that	NULL
are	NULL
required	NULL
for	NULL
phosphorylation-in-duced	NULL
degradation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
HA-tagged	NULL
BCL-6	NULL
proteins	NULL
.	NULL

PEST	NULL
sequences	NULL
were	NULL
identified	NULL
by	NULL
the	NULL
PEST-FIND	NULL
program	NULL
.	NULL

PESTI	NULL
:	NULL
AA336-AA351	NULL
IZIIIIZI	NULL
Pox	NULL
HA-BCL-64	NULL
(	NULL
300-417	NULL
)	NULL
121	NULL
(	NULL
KSDCQPNSPTESCSSK	NULL
)	NULL
,	NULL
score	NULL
9.4	NULL
;	NULL
PEST2	NULL
:	NULL
AA365-AA371	NULL
(	NULL
KSPTDPK	NULL
)	NULL
,	NULL
score	NULL
5.0	NULL
;	NULL
PEST3	NULL
:	NULL
AA406-AA430	NULL
(	NULL
RAYTAPPAC-QPPMEPENLDLQSPTK	NULL
)	NULL
,	NULL
score	NULL
2.6	NULL
.	NULL

(	NULL
B	NULL
)	NULL
293T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
pMT2T	NULL
vectors	NULL
expressing	NULL
HA-BCL-6	NULL
(	NULL
lanes	NULL
1-3	NULL
)	NULL
,	NULL
HA-BCL-6A	NULL
(	NULL
300-417	NULL
)	NULL
(	NULL
Lanes	NULL
4-6	NULL
)	NULL
,	NULL
or	NULL
HA-BCL-6ZF	NULL
(	NULL
lanes	NULL
7-9	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
MEK-2E	NULL
(	NULL
lanes	NULL
1,4,7	NULL
)	NULL
or	NULL
in	NULL
the	NULL
H	NULL
&	NULL
A	NULL
presence	NULL
of	NULL
increasing	NULL
amount	NULL
(	NULL
5	NULL
,	NULL
10	NULL
ug	NULL
)	NULL
of	NULL
97	NULL
MEK-2E	NULL
(	NULL
lanes	NULL
2,5,8,3,6,9	NULL
)	NULL
.	NULL

Forty-eight	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
equal	NULL
amounts	NULL
of	NULL
cell	NULL
lysates	NULL
were	NULL
analyzed	NULL
(	NULL
after	NULL
normalization	NULL
for	NULL
transfection	NULL
efficency	NULL
based	NULL
on	NULL
B-galactosidase	NULL
activity	NULL
of	NULL
cotransfected	NULL
plas-mids	NULL
)	NULL
by	NULL
8	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
Western	NULL
blot	NULL
using	NULL
anti-HA	NULL
(	NULL
12CA5	NULL
)	NULL
antibodies	NULL
.	NULL

tein	NULL
containing	NULL
all	NULL
three	NULL
PEST	NULL
sequences	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
MAPK-induced	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
BCL-6	NULL
target	NULL
PEST	NULL
sequences	NULL
located	NULL
in	NULL
the	NULL
same	NULL
domain	NULL
as	NULL
the	NULL
MAPK	NULL
phosphorylation	NULL
sites	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
PEST	NULL
sequences	NULL
suggested	NULL
that	NULL
MAPK-induced	NULL
BCL-6	NULL
degradation	NULL
could	NULL
be	NULL
mediated	NULL
by	NULL
the	NULL
ubiquitin/proteasome	NULL
pathway	NULL
(	NULL
Hochstrasser	NULL
1996	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
MEK-2E	NULL
mediated	NULL
degradation	NULL
of	NULL
BCL-6	NULL
in	NULL
transfected	NULL
293T	NULL
cells	NULL
could	NULL
be	NULL
inhibited	NULL
by	NULL
the	NULL
proteasome	NULL
inhibitor	NULL
Cbz-LLL	NULL
(	NULL
MG132	NULL
)	NULL
(	NULL
Kim	NULL
and	NULL
Maniatis	NULL
1996	NULL
;	NULL
Palom	NULL
bella	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Rock	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
)	NULL
.	NULL

Figure	NULL
4A	NULL
shows	NULL
that	NULL
BCL-6	NULL
degradation	NULL
was	NULL
completely	NULL
inhibited	NULL
by	NULL
MG132	NULL
,	NULL
but	NULL
not	NULL
by	NULL
DMSO	NULL
(	NULL
solvent	NULL
control	NULL
)	NULL
or	NULL
calpain	NULL
inhibitor	NULL
II	NULL
(	NULL
CI	NULL
II	NULL
)	NULL
,	NULL
a	NULL
cysteine-protease	NULL
inhibitor	NULL
(	NULL
Kim	NULL
and	NULL
Maniatis	NULL
1996	NULL
;	NULL
Palombella	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
addition	NULL
of	NULL
multiple	NULL
ubiquitins	NULL
to	NULL
the	NULL
proteolysis	NULL
substrate	NULL
is	NULL
a	NULL
key	NULL
step	NULL
preceding	NULL
target	NULL
degradation	NULL
by	NULL
the	NULL
proteasome	NULL
,	NULL
we	NULL
then	NULL
tested	NULL
whether	NULL
BCL-6/ubiquitin	NULL
conjugates	NULL
in	NULL
vivo	NULL
could	NULL
be	NULL
detected	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
293T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
vectors	NULL
expressing	NULL
BCL-6	NULL
,	NULL
MEK-2E	NULL
,	NULL
and	NULL
epitope	NULL
(	NULL
His	NULL
,	NULL
)	NULL
-tagged	NULL
ubiquitin	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
MG132	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
subjected	NULL
to	NULL
imm	NULL
with	NULL
anti-BCL-6	NULL
antibodies	NULL
,	NULL
and	NULL
the	NULL
im	NULL
munoprecipitates	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
using	NULL
anti-ubiquitin	NULL
antibodies	NULL
.	NULL

Figure	NULL
4B	NULL
shows	NULL
that	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
MG132	NULL
,	NULL
low	NULL
levels	NULL
of	NULL
BCL-6/ubiquitin	NULL
were	NULL
detectable	NULL
when	NULL
BCL-6	NULL
1956	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
MEK-2E	NULL
1	NULL
POZ	NULL
L	NULL
&	NULL
+	NULL
++	NULL
<	NULL
HA-BCL-6	NULL
€	NULL
HA-BCL-6A	NULL
(	NULL
300-17	NULL
)	NULL
CDAD	NULL
and	NULL
ubiquitin	NULL
were	NULL
coexpressed	NULL
with	NULL
exogenous	NULL
MEK-2E	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
;	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
MG132	NULL
,	NULL
typical	NULL
ladders	NULL
representing	NULL
multi-ubiquitinated	NULL
forms	NULL
of	NULL
BCL-6	NULL
were	NULL
detectable	NULL
at	NULL
high	NULL
levels	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
MEK-2E	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
;	NULL
low	NULL
levels	NULL
were	NULL
detectable	NULL
also	NULL
in	NULL
its	NULL
absence	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
normal	NULL
turnover	NULL
of	NULL
BCL-6	NULL
degradation	NULL
may	NULL
be	NULL
mediated	NULL
by	NULL
basal	NULL
levels	NULL
of	NULL
endogenous	NULL
MAPK	NULL
activity	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
specific	NULL
pharmacological	NULL
inhibition	NULL
and	NULL
the	NULL
detection	NULL
of	NULL
MEK-2E-inducible	NULL
BCL-6/ubiquitin	NULL
conjugates	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
MAPK-induced	NULL
phosphorylation	NULL
induces	NULL
degradation	NULL
of	NULL
BCL-6	NULL
via	NULL
the	NULL
ubiquitin/proteasome	NULL
pathway	NULL
.	NULL

MA	NULL
PK-m	NULL
ediated	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
of	NULL
BCL-6	NULL
is	NULL
induced	NULL
by	NULL
antigen-receptor	NULL
signaling	NULL
in	NULL
B	NULL
cells	NULL
To	NULL
demonstrate	NULL
the	NULL
physiological	NULL
significance	NULL
of	NULL
MAPK-mediated	NULL
phosphorylation/degradation	NULL
of	NULL
BCL-6	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
we	NULL
treated	NULL
a	NULL
B-cell	NULL
lymphoma	NULL
cell	NULL
line	NULL
(	NULL
Ramos	NULL
)	NULL
with	NULL
anti-IgM	NULL
antibodies	NULL
,	NULL
a	NULL
treatment	NULL
that	NULL
mimics	NULL
B-cell	NULL
antigen-receptor	NULL
signaling	NULL
and	NULL
specifically	NULL
activates	NULL
MAPK	NULL
(	NULL
ERK2	NULL
)	NULL
(	NULL
Gold	NULL
et	NULL
al	NULL
.	NULL

1992	NULL
;	NULL
Sakata	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Sutherland	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

As	NULL
previously	NULL
demonstrated	NULL
,	NULL
an	NULL
in	NULL
vitro	NULL
assay	NULL
showed	NULL
that	NULL
ERK2	NULL
kinase	NULL
activity	NULL
was	NULL
rapidly	NULL
increased	NULL
5	NULL
min	NULL
after	NULL
anti-IgM	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
this	NULL
was	NULL
followed	NULL
by	NULL
hyperphosphorylation	NULL
of	NULL
ERK2	NULL
and	NULL
DMSQ	NULL
CI	NULL
II	NULL
MG1IS2	NULL
MEK-BE	NULL
|	NULL
>	NULL
-	NULL
#	NULL
40	NULL
-	NULL
#	NULL
40	NULL
-	NULL
40+	NULL
(	NULL
xD	NULL
)	NULL
97.4	NULL
~	NULL
Wing	NULL
-	NULL
<	NULL
-	NULL
-	NULL
BCL-G	NULL
43	NULL
-mg-	NULL
~-	NULL
Sher	NULL
*	NULL
10	NULL
2	NULL
B	NULL
4	NULL
50	NULL
6	NULL
T	NULL
&	NULL
A	NULL
9	NULL
B	NULL
MGTS2	NULL
mo	NULL
8	NULL
8	NULL
so	NULL
o	NULL
040	NULL
4	NULL
4	NULL
MEK-2E	NULL
ae	NULL
+	NULL
Hisg-Ub	NULL
moe	NULL
$	NULL
e	NULL
#	NULL
+	NULL
0	NULL
4	NULL
0	NULL
#	NULL
04	NULL
BCL-6	NULL
&	NULL
00.0	NULL
40	NULL
4	NULL
O4	NULL
+0	NULL
+	NULL
w-	NULL
——-	NULL
,	NULL
we	NULL
``	NULL
~-	NULL
vag	NULL
kD	NULL
]	NULL
]	NULL
HCLé-Ub	NULL
Ba	NULL
Figure	NULL
4	NULL
.	NULL

MAPK-induced	NULL
BCL-6	NULL
degradation	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
ubiquitin/proteasome	NULL
pathway	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
BCL-6	NULL
proteins	NULL
in	NULL
293T	NULL
cells	NULL
transfected	NULL
with	NULL
BCL-6	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
cotransfected	NULL
MEK-2E	NULL
treated	NULL
with	NULL
0.2	NULL
%	NULL
DMSO	NULL
(	NULL
anes	NULL
1-3	NULL
)	NULL
,	NULL
50	NULL
um	NULL
Calpain	NULL
inhibitor	NULL
II	NULL
(	NULL
Lanes	NULL
4-6	NULL
)	NULL
,	NULL
or	NULL
50	NULL
uM	NULL
MG132	NULL
(	NULL
lanes	NULL
7-9	NULL
)	NULL
(	NULL
added	NULL
8	NULL
hr	NULL
after	NULL
transfection	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
293T	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
BCL-6	NULL
,	NULL
His	NULL
,	NULL
-Ub	NULL
,	NULL
and	NULL
MEK-2E	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
I-4	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
MG132	NULL
(	NULL
lanes	NULL
5-8	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
imm	NULL
unoprecipitated	NULL
with	NULL
anti-BCL-6	NULL
antibodies	NULL
(	NULL
N-70-6	NULL
)	NULL
and	NULL
the	NULL
immunoprecipitants	NULL
were	NULL
analyzed	NULL
by	NULL
6	NULL
%	NULL
SDS-PAGE	NULL
followed	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
using	NULL
anti-ubiquitin	NULL
antibodies	NULL
.	NULL

BCL-6	NULL
(	NULL
note	NULL
the	NULL
slow	NULL
-migrating	NULL
bands	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
and	NULL
by	NULL
the	NULL
disappearance	NULL
of	NULL
BCL-6	NULL
,	NULL
but	NULL
not	NULL
ERK2	NULL
.	NULL

In	NULL
the	NULL
same	NULL
experiment	NULL
,	NULL
Northern	NULL
blot	NULL
analysis	NULL
showed	NULL
that	NULL
bel-6	NULL
mRN	NULL
A	NULL
levels	NULL
did	NULL
not	NULL
change	NULL
during	NULL
anti-IgM	NULL
treatment	NULL
of	NULL
Ram	NULL
os	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
bottom	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
hyperphosphorylation	NULL
was	NULL
associated	NULL
with	NULL
increased	NULL
BCL-6	NULL
instability	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
half-life	NULL
of	NULL
BCL-6	NULL
in	NULL
anti-IgM	NULL
-treated	NULL
Ram	NULL
os	NULL
cells	NULL
by	NULL
a	NULL
``	NULL
pulse-chase	NULL
``	NULL
labeling	NULL
experiment	NULL
.	NULL

The	NULL
results	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
showed	NULL
that	NULL
the	NULL
hyperphosphorylated	NULL
(	NULL
slow-migrating	NULL
)	NULL
forms	NULL
of	NULL
BCL-6	NULL
were	NULL
significantly	NULL
less	NULL
stable	NULL
than	NULL
the	NULL
hypophosphorylated	NULL
(	NULL
fast-migrating	NULL
)	NULL
forms	NULL
(	NULL
half	NULL
life	NULL
4-6	NULL
hr	NULL
)	NULL
Anti-IgM-induced	NULL
BCL-6	NULL
degradation	NULL
was	NULL
dependent	NULL
on	NULL
phosphorylation	NULL
as	NULL
it	NULL
was	NULL
inhibited	NULL
by	NULL
a	NULL
specific	NULL
MAPK	NULL
inhibitor	NULL
PDO098059	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
(	NULL
Dudley	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Pang	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
,	NULL
and	NULL
was	NULL
mediated	NULL
by	NULL
the	NULL
ubiquitin/proteasome	NULL
pathway	NULL
since	NULL
it	NULL
was	NULL
specifically	NULL
inhibited	NULL
by	NULL
MG132	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
anti-IgM	NULL
treatment	NULL
of	NULL
Ramos	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
cadmium	NULL
inducible	NULL
vectors	NULL
expressing	NULL
HA-tagged	NULL
wild-type	NULL
,	NULL
333/343	NULL
mutant	NULL
,	NULL
or	NULL
amino-terminal	NULL
Regulation	NULL
of	NULL
BCL-6	NULL
by	NULL
antigen	NULL
receptor	NULL
signaling	NULL
deleted	NULL
BCL-6	NULL
proteins	NULL
showed	NULL
that	NULL
degradation	NULL
required	NULL
phosphorylation	NULL
of	NULL
the	NULL
333	NULL
and	NULL
343	NULL
serines	NULL
as	NULL
well	NULL
as	NULL
the	NULL
amino-terminal	NULL
half	NULL
of	NULL
BCL-6	NULL
containing	NULL
the	NULL
PEST	NULL
motifs	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
MAPK-mediated	NULL
phosphorylation	NULL
of	NULL
BCL-6	NULL
and	NULL
its	NULL
degradation	NULL
by	NULL
the	NULL
ubiquitin/proteasome	NULL
pathway	NULL
represent	NULL
a	NULL
physi-ologic	NULL
pathway	NULL
that	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
antigen-receptor	NULL
signling	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Discussion	NULL
The	NULL
present	NULL
study	NULL
identifies	NULL
a	NULL
signal	NULL
transduction	NULL
pathway	NULL
by	NULL
which	NULL
the	NULL
antigen	NULL
receptor	NULL
regulates	NULL
the	NULL
stability	NULL
of	NULL
the	NULL
BCL-6	NULL
transcription	NULL
factor	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
results	NULL
have	NULL
im	NULL
plications	NULL
for	NULL
the	NULL
normal	NULL
mechanism	NULL
regulating	NULL
GC	NULL
formation	NULL
as	NULL
well	NULL
as	NULL
for	NULL
the	NULL
role	NULL
of	NULL
deregulated	NULL
bel-6	NULL
expression	NULL
in	NULL
lymphomas	NULL
deriving	NULL
from	NULL
GC	NULL
B	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
several	NULL
observations	NULL
suggest	NULL
that	NULL
MAPK-mediated	NULL
regulation	NULL
of	NULL
POZ/Zinc	NULL
finger	NULL
protein	NULL
stability	NULL
may	NULL
represent	NULL
a	NULL
general	NULL
,	NULL
highly	NULL
conserved	NULL
regulatory	NULL
mechanism	NULL
in	NULL
eukaryotic	NULL
cells	NULL
.	NULL

Regulation	NULL
of	NULL
BCL-6	NULL
stability	NULL
during	NULL
GC	NULL
form	NULL
ation	NULL
The	NULL
finding	NULL
that	NULL
antigen-receptor-induced	NULL
activation	NULL
of	NULL
MAPK	NULL
leads	NULL
to	NULL
BCL-6	NULL
degradation	NULL
must	NULL
be	NULL
seen	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
complex	NULL
network	NULL
of	NULL
signals	NULL
modulating	NULL
receptor	NULL
signaling	NULL
in	NULL
GC	NULL
Bcells	NULL
(	NULL
Tedder	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
;	NULL
Cam-bier	NULL
1997	NULL
)	NULL
.	NULL

During	NULL
GC	NULL
formation	NULL
,	NULL
activation	NULL
of	NULL
this	NULL
pathway	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
pre-GC	NULL
B	NULL
cells	NULL
in	NULL
the	NULL
follicular	NULL
mantle	NULL
zone	NULL
,	NULL
the	NULL
site	NULL
where	NULL
B	NULL
cells	NULL
encounter	NULL
the	NULL
antigen	NULL
,	NULL
express	NULL
bel/-6	NULL
RNA	NULL
,	NULL
but	NULL
not	NULL
the	NULL
BCL-6	NULL
protein	NULL
(	NULL
Allman	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Cattoretti	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

Within	NULL
the	NULL
GC	NULL
,	NULL
the	NULL
coexistence	NULL
of	NULL
antigen	NULL
and	NULL
bel-6	NULL
expression	NULL
implies	NULL
that	NULL
antigen-receptor	NULL
signaling	NULL
must	NULL
be	NULL
modulated	NULL
by	NULL
mechanisms	NULL
that	NULL
allow	NULL
BCL-6	NULL
stability	NULL
.	NULL

These	NULL
mechanisms	NULL
may	NULL
include	NULL
down-regulation	NULL
of	NULL
antigen-receptor	NULL
expression	NULL
in	NULL
centroblasts	NULL
(	NULL
MacLennan	NULL
1994	NULL
)	NULL
,	NULL
modulation	NULL
of	NULL
receptor	NULL
signaling	NULL
by	NULL
CD22	NULL
or	NULL
Fc	NULL
y	NULL
receptor	NULL
(	NULL
Tedder	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
;	NULL
Cam	NULL
bier	NULL
1997	NULL
)	NULL
,	NULL
and	NULL
the	NULL
activity	NULL
of	NULL
de-ubiquitinases	NULL
(	NULL
DUB	NULL
)	NULL
,	NULL
which	NULL
regulate	NULL
substrate	NULL
ubiquitination	NULL
and	NULL
are	NULL
induced	NULL
by	NULL
cytokines	NULL
acting	NULL
on	NULL
GC	NULL
B	NULL
cells	NULL
(	NULL
Zhu	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

During	NULL
post-GC	NULL
differentiation	NULL
,	NULL
antigen-induced	NULL
degradation	NULL
may	NULL
serve	NULL
as	NULL
a	NULL
rapid	NULL
mechanism	NULL
to	NULL
down-regulate	NULL
be/-6	NULL
expression	NULL
,	NULL
in	NULL
synergy	NULL
with	NULL
transcriptional	NULL
down-regulation	NULL
by	NULL
CD40	NULL
signaling	NULL
(	NULL
Allman	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Cattoretti	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
regulation	NULL
of	NULL
BCL-6	NULL
stability	NULL
during	NULL
GC	NULL
development	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
affected	NULL
by	NULL
various	NULL
additional	NULL
signals	NULL
that	NULL
activate	NULL
MAPK	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
including	NULL
various	NULL
cytokines	NULL
(	NULL
TNF	NULL
,	NULL
IL-6	NULL
,	NULL
IL-2	NULL
)	NULL
(	NULL
Vietor	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Minami	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Fukada	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
these	NULL
signals	NULL
on	NULL
the	NULL
pathway	NULL
linking	NULL
the	NULL
antigen	NULL
receptor	NULL
to	NULL
BCL-6	NULL
can	NULL
be	NULL
tested	NULL
in	NULL
the	NULL
experimental	NULL
systems	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

Im	NULL
plication	NULL
for	NULL
lym	NULL
phom	NULL
agenesis	NULL
Most	NULL
B-cell	NULL
lymphoma	NULL
types	NULL
,	NULL
FL	NULL
,	NULL
DLCL	NULL
,	NULL
and	NULL
Burkitt	NULL
(	NULL
BL	NULL
)	NULL
lymphoma	NULL
,	NULL
are	NULL
thought	NULL
to	NULL
derive	NULL
from	NULL
the	NULL
GC	NULL
B	NULL
cells	NULL
.	NULL

Although	NULL
rearrangements	NULL
and/or	NULL
mutations	NULL
of	NULL
the	NULL
bel-6	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
1957	NULL
Niu	NULL
et	NULL
al	NULL
.	NULL

A	NULL
C	NULL
Anti-ight	NULL
[	NULL
Time	NULL
)	NULL
{	NULL
(	NULL
5	NULL
15	NULL
3	NULL
th	NULL
Sh	NULL
4h	NULL
&	NULL
Tme	NULL
-	NULL
f	NULL
15°	NULL
30	NULL
2h	NULL
4h	NULL
Sh	NULL
DMSO	NULL
Coo	NULL
``	NULL
JBCL-6	NULL
tes	NULL
wap	NULL
ag	NULL
sem	NULL
woe	NULL
de	NULL
em	NULL
em	NULL
n	NULL
em	NULL
e	NULL
mem	NULL
-	NULL
]	NULL
ENEL	NULL
mee	NULL
tam	NULL
mam	NULL
mes	NULL
mes	NULL
wall	NULL
20032059	NULL
D	NULL
o	NULL
C	NULL
i138	NULL
%	NULL
1-H-	NULL
MW	NULL
<	NULL
mor	NULL
DMSO	NULL
CII	NULL
MG1Es	NULL
®	NULL
treatment	NULL
(	NULL
hr	NULL
}	NULL
Q	NULL
2	NULL
4	NULL
60	NULL
2	NULL
4	NULL
60	NULL
2	NULL
4	NULL
6	NULL
1	NULL
BR	NULL
&	NULL
4	NULL
5060	NULL
Tog	NULL
(	NULL
KD	NULL
)	NULL
B7.4	NULL
``	NULL
Hag	NULL
wer	NULL
imen	NULL
woe	NULL
mee	NULL
geat	NULL
.	NULL

+-	NULL
BCL-G	NULL
las	NULL
lak	NULL
ta	NULL
li	NULL
tat	NULL
te	NULL
tat	NULL
aas	NULL
.	NULL

5C	NULL
oc	NULL
mis	NULL
660	NULL
43	NULL
(	NULL
mo	NULL
O	NULL
emm	NULL
iy	NULL
,	NULL
.	NULL

Sem	NULL
--	NULL
ao	NULL
mm	NULL
at	NULL
mee	NULL
mee	NULL
a	NULL
*	NULL
1	NULL
2	NULL
3	NULL
&	NULL
5	NULL
6	NULL
7	NULL
l	NULL
9	NULL
10	NULL
B	NULL
3	NULL
pg	NULL
2	NULL
E	NULL
E	NULL
Aundti-I	NULL
git	NULL
4	NULL
<	NULL
a	NULL
car+	NULL
of	NULL
wor	NULL
Time	NULL
-	NULL
&	NULL
h	NULL
Oh	NULL
1h	NULL
2	NULL
4h	NULL
6h	NULL
o	NULL
af	NULL
:	NULL
th	NULL
2h	NULL
4h	NULL
6h	NULL
F	NULL
may	NULL
e®	NULL
mes	NULL
==	NULL
ss	NULL
€-BA-BCL	NULL
-S	NULL
wwe	NULL
O	NULL
AE	NULL
31s	NULL
o	NULL
HD	NULL
&	NULL
ccu-szr	NULL
ok	NULL
-	NULL
1°	NULL
2	NULL
3	NULL
4	NULL
§	NULL
6	NULL
``	NULL
'	NULL
&	NULL
]	NULL
BCl-6	NULL
Figure	NULL
5	NULL
.	NULL

BCL-6	NULL
is	NULL
phosphorylated	NULL
and	NULL
degraded	NULL
by	NULL
antigen-receptor	NULL
signaling	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Ramos	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10°/m1	NULL
)	NULL
were	NULL
treated	NULL
with	NULL
anti-IgM	NULL
(	NULL
10	NULL
ug/m1	NULL
)	NULL
and	NULL
harvested	NULL
at	NULL
different	NULL
time	NULL
points	NULL
after	NULL
treatment	NULL
as	NULL
indicated	NULL
.	NULL

(	NULL
4	NULL
)	NULL
(	NULL
Top	NULL
three	NULL
panels	NULL
)	NULL
Equal	NULL
amounts	NULL
of	NULL
cell	NULL
extracts	NULL
were	NULL
used	NULL
for	NULL
Western	NULL
blot	NULL
analysis	NULL
using	NULL
anti-BCL-6	NULL
(	NULL
top	NULL
)	NULL
,	NULL
or	NULL
anti-ERK2	NULL
(	NULL
middle	NULL
)	NULL
antibodies	NULL
,	NULL
and	NULL
for	NULL
solid-phase	NULL
ERK2	NULL
kinase	NULL
assays	NULL
(	NULL
MBP	NULL
,	NULL
bottom	NULL
)	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
RN	NULL
As	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
were	NULL
used	NULL
for	NULL
Northern	NULL
blot	NULL
analysis	NULL
with	NULL
BCL-6	NULL
or	NULL
GAPDH	NULL
probes	NULL
(	NULL
bottom	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Hyperphosphorylated	NULL
BCL-6	NULL
proteins	NULL
are	NULL
more	NULL
unstable	NULL
.	NULL

Ramos	NULL
cells	NULL
were	NULL
pulse	NULL
labeled	NULL
for	NULL
1	NULL
hr	NULL
with	NULL
[	NULL
P°SJmethionine	NULL
and	NULL
RSJcysteine	NULL
,	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
anti-IgM	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
for	NULL
30	NULL
min	NULL
and	NULL
subsequently	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
excess	NULL
of	NULL
nonradioactive	NULL
methionine	NULL
and	NULL
cysteine	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
(	NULL
chase	NULL
)	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-BCL-6	NULL
antibodies	NULL
and	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
followed	NULL
by	NULL
autoradiography	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Anti-IgM	NULL
induced	NULL
BCL-6	NULL
phosphorylation	NULL
and	NULL
degradation	NULL
is	NULL
prevented	NULL
by	NULL
a	NULL
specific	NULL
MEK	NULL
inhibitor	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
BCL-6	NULL
in	NULL
Ramos	NULL
cells	NULL
treated	NULL
with	NULL
anti-IgM	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.2	NULL
%	NULL
DMSO	NULL
or	NULL
50	NULL
um	NULL
PDO98059	NULL
(	NULL
added	NULL
30	NULL
min	NULL
before	NULL
anti-IgM	NULL
treatment	NULL
)	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Anti-IgM	NULL
induced	NULL
BCL-6	NULL
degradation	NULL
is	NULL
prevented	NULL
by	NULL
a	NULL
specific	NULL
proteasome	NULL
inhibitor	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
BCL-6	NULL
in	NULL
Ramos	NULL
cells	NULL
treated	NULL
with	NULL
anti-IgM	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.2	NULL
%	NULL
DMSO	NULL
(	NULL
lanes	NULL
2-4	NULL
)	NULL
,	NULL
50	NULL
um	NULL
Calpain	NULL
inhibitor	NULL
I	NULL
(	NULL
lanes	NULL
5-7	NULL
)	NULL
,	NULL
and	NULL
50	NULL
um	NULL
MG132	NULL
(	NULL
lanes	NULL
8-70	NULL
)	NULL
(	NULL
added	NULL
1	NULL
hr	NULL
before	NULL
the	NULL
treatment	NULL
)	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Mutant	NULL
BCL-6	NULL
proteins	NULL
are	NULL
resistant	NULL
to	NULL
anti-IgM-induced	NULL
degradation	NULL
.	NULL

Ramos	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
pHeBo-MT-HA-BCL6	NULL
,	NULL
pHeBo-MT-HA-BCL-6a	NULL
;	NULL
,553,343	NULL
and	NULL
pHeBo-MT-HA-BCL6ZF	NULL
were	NULL
treated	NULL
with	NULL
1	NULL
um	NULL
CdCl	NULL
,	NULL
for	NULL
6	NULL
hr	NULL
to	NULL
induce	NULL
exogenous	NULL
BCL-6	NULL
expression	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
treated	NULL
wth	NULL
anti-IgM	NULL
(	NULL
10	NULL
ug/m1	NULL
)	NULL
and	NULL
harvested	NULL
at	NULL
different	NULL
time	NULL
points	NULL
as	NULL
indicated	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
cell	NULL
extracts	NULL
were	NULL
loaded	NULL
on	NULL
7	NULL
%	NULL
(	NULL
HA-BCL-6	NULL
or	NULL
HA-BCL-6a1,333,343	NULL
)	NULL
or	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
(	NULL
HA-BCL-6ZF	NULL
)	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
exogenous	NULL
BCL-6	NULL
proteins	NULL
were	NULL
analyzed	NULL
by	NULL
Western	NULL
blot	NULL
using	NULL
anti-HA	NULL
antibodies	NULL
(	NULL
12CA5	NULL
)	NULL
.	NULL

regulatory	NULL
region	NULL
are	NULL
found	NULL
most	NULL
frequently	NULL
in	NULL
DLCL	NULL
and	NULL
FL	NULL
,	NULL
all	NULL
GC-derived	NULL
lymphomas	NULL
,	NULL
including	NULL
those	NULL
carrying	NULL
a	NULL
structurally	NULL
normal	NULL
bei-6	NULL
gene	NULL
,	NULL
express	NULL
the	NULL
BCL-6	NULL
protein	NULL
(	NULL
Cattoretti	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

This	NULL
implies	NULL
that	NULL
the	NULL
BCL-6	NULL
protein	NULL
is	NULL
stable	NULL
in	NULL
tumor	NULL
cells	NULL
and	NULL
suggests	NULL
that	NULL
MAPK-mediated	NULL
degradation	NULL
may	NULL
be	NULL
blocked	NULL
by	NULL
genetic	NULL
or	NULL
epi-genetic	NULL
alterations	NULL
affecting	NULL
the	NULL
pathway	NULL
leading	NULL
to	NULL
BCL-6	NULL
degradation	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
BCL-6	NULL
degradation	NULL
can	NULL
be	NULL
triggered	NULL
from	NULL
the	NULL
cell	NULL
surface	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
antigen	NULL
receptor	NULL
has	NULL
potential	NULL
relevance	NULL
for	NULL
the	NULL
therapy	NULL
of	NULL
B-cell	NULL
lymphoma	NULL
.	NULL

1958	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
MA	NULL
PK-m	NULL
ediated	NULL
regulation	NULL
of	NULL
POZ/zinc	NULL
finger	NULL
transcription	NULL
factors	NULL
MAPK	NULL
is	NULL
a	NULL
ubiquitous	NULL
,	NULL
evolutionarily	NULL
conserved	NULL
signal	NULL
transducer	NULL
that	NULL
is	NULL
activated	NULL
by	NULL
heterogeneous	NULL
signals	NULL
that	NULL
originate	NULL
from	NULL
the	NULL
cell	NULL
membrane	NULL
and	NULL
are	NULL
trans-duced	NULL
to	NULL
MAPK	NULL
via	NULL
RAS	NULL
proteins	NULL
(	NULL
Gold	NULL
and	NULL
Matsuuchi	NULL
1995	NULL
;	NULL
Alberola-lla	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
POZ/zinc	NULL
finger	NULL
proteins	NULL
represent	NULL
a	NULL
large	NULL
family	NULL
of	NULL
highly	NULL
conserved	NULL
transcription	NULL
factors	NULL
including	NULL
Drosophila	NULL
cell	NULL
fate	NULL
regulators	NULL
such	NULL
as	NULL
Tram	NULL
track	NULL
and	NULL
Broad-com	NULL
plex	NULL
,	NULL
as	NULL
well	NULL
as	NULL
human	NULL
cancer-associated	NULL
proteins	NULL
such	NULL
as	NULL
BCL-6	NULL
and	NULL
PLZF	NULL
.	NULL

These	NULL
molecules	NULL
have	NULL
strong	NULL
structural	NULL
(	NULL
POZ	NULL
and	NULL
ZF	NULL
domains	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
functional	NULL
homologies	NULL
being	NULL
transcriptional	NULL
repressors	NULL
that	NULL
control	NULL
cell	NULL
differentiation	NULL
(	NULL
Chen	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Emery	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Albagli	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

Most	NULL
notably	NULL
,	NULL
POZ	NULL
finger	NULL
proteins	NULL
also	NULL
carry	NULL
possible	NULL
MAPK	NULL
phosphorylation	NULL
sites	NULL
and	NULL
PEST	NULL
sequences	NULL
in	NULL
approximately	NULL
the	NULL
same	NULL
position	NULL
as	NULL
those	NULL
carried	NULL
by	NULL
BCL-6	NULL
(	NULL
H.	NULL
Niu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
unpubl	NULL
.	NULL
)	NULL

.	NULL

In	NULL
Drosophila	NULL
,	NULL
degradation	NULL
of	NULL
TTK88	NULL
,	NULL
a	NULL
POZ/zinc	NULL
finger	NULL
inhibitor	NULL
of	NULL
neural-cell	NULL
differentiation	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
MAPK	NULL
(	NULL
Li	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
;	NULL
Tang	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
degradation	NULL
of	NULL
POZ/zinc	NULL
finger	NULL
transcription	NULL
factors	NULL
may	NULL
represent	NULL
a	NULL
general	NULL
mechanism	NULL
by	NULL
which	NULL
the	NULL
RAS/	NULL
MAPK	NULL
pathway	NULL
controls	NULL
cell	NULL
function	NULL
and	NULL
differentiation	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Reagents	NULL
and	NULL
plasm	NULL
ids	NULL
Goat	NULL
anti-human	NULL
IgM	NULL
(	NULL
u-heavy	NULL
chain	NULL
specific	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Southern	NULL
Biotechnology	NULL
.	NULL

Polyclonal	NULL
anti-BCL-6	NULL
(	NULL
N-70-6	NULL
)	NULL
antiserum	NULL
was	NULL
produced	NULL
by	NULL
using	NULL
the	NULL
amino-terminal	NULL
peptides	NULL
of	NULL
BCL-6	NULL
(	NULL
Cattoretti	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

Monoclonal	NULL
mouse	NULL
anti-ERK2	NULL
(	NULL
C-14	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biothechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
Monoclonal	NULL
mouse	NULL
anti-ubiquitin	NULL
was	NULL
obtained	NULL
from	NULL
Zymed	NULL
Laboratories	NULL
(	NULL
South	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Monoclonal	NULL
mouse	NULL
anti-HA	NULL
(	NULL
12CA5	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
as	NULL
was	NULL
Calpain	NULL
Inhibitor	NULL
II	NULL
.	NULL

Protein	NULL
A-Sepharose	NULL
CL-4B	NULL
and	NULL
glutathione-Sepharose	NULL
were	NULL
purchased	NULL
from	NULL
Phar-macia	NULL
.	NULL

Myelin	NULL
basic	NULL
protein	NULL
(	NULL
MBP	NULL
)	NULL
and	NULL
N-CBZ-Leu-Leu-Leu-AL	NULL
(	NULL
MG132	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
.	NULL

PDO98059	NULL
was	NULL
purchased	NULL
from	NULL
Calbiochem-Novabiochem	NULL
(	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
The	NULL
GST-BCL6	NULL
,	NULL
GST-BCL6AZF	NULL
,	NULL
GST-BCL6ZF	NULL
,	NULL
and	NULL
GST-BCL6AZFa	NULL
)	NULL
,	NULL
;	NULL
33,343	NULL
fusion	NULL
proteins	NULL
were	NULL
produced	NULL
by	NULL
pGEX-2TK-based	NULL
plasmids	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
containing	NULL
full-length	NULL
,	NULL
deletion	NULL
,	NULL
or	NULL
point	NULL
mutants	NULL
of	NULL
bel-6	NULL
.	NULL

The	NULL
point	NULL
mutations	NULL
(	NULL
Ala333	NULL
,	NULL
Ala343	NULL
)	NULL
were	NULL
generated	NULL
by	NULL
PCR-based	NULL
methods	NULL
;	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
resulting	NULL
plasmids	NULL
was	NULL
confirmed	NULL
by	NULL
nucleotide	NULL
sequence	NULL
analysis	NULL
.	NULL

pMT2T-BCL-6	NULL
and	NULL
B6BS-TK-LUC	NULL
have	NULL
been	NULL
described	NULL
as	NULL
previous	NULL
(	NULL
Chang	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
pMT2T-BCL-Saiass3,343	NULL
was	NULL
constructed	NULL
by	NULL
transferring	NULL
the	NULL
Bell-N.eol	NULL
!	NULL

fragments	NULL
of	NULL
plasmid	NULL
into	NULL
the	NULL
pMT2T-BCL-6	NULL
vector	NULL
.	NULL

MEK-2E-EE-CMV	NULL
and	NULL
MEK-EE-CMV	NULL
for	NULL
expressing	NULL
of	NULL
constitutively	NULL
active	NULL
or	NULL
inactive	NULL
MEK	NULL
were	NULL
provided	NULL
by	NULL
Dr.	NULL
D.	NULL
Templeton	NULL
(	NULL
Case	NULL
Western	NULL
Reserve	NULL
University	NULL
,	NULL
Cleveland	NULL
,	NULL
OH	NULL
)	NULL
.	NULL

The	NULL
pMT2T-HA-BCL-6	NULL
,	NULL
pMT2T-HA-BCL-6A	NULL
(	NULL
300-417	NULL
)	NULL
,	NULL
and	NULL
pMT2T-HA-BCL-6ZF	NULL
vectors	NULL
were	NULL
constructed	NULL
by	NULL
inserting	NULL
the	NULL
sequences	NULL
encoding	NULL
the	NULL
HA	NULL
epitope	NULL
upstream	NULL
and	NULL
in	NULL
frame	NULL
with	NULL
bel-6	NULL
coding	NULL
sequences	NULL
.	NULL

Deletion	NULL
mutants	NULL
of	NULL
bel-6	NULL
were	NULL
produced	NULL
by	NULL
PCR-based	NULL
methods	NULL
and	NULL
confirmed	NULL
by	NULL
sequencing	NULL
.	NULL

Hisg-ubiquitin-CMV	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
T.	NULL
Maniatis	NULL
(	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Episomally	NULL
replicating	NULL
plasmid	NULL
pHeBo-MT	NULL
,	NULL
which	NULL
carries	NULL
EBV	NULL
oriP	NULL
,	NULL
hygromycin	NULL
B	NULL
,	NULL
and	NULL
MT	NULL
promoter	NULL
efficiently	NULL
yields	NULL
hygro-mycin-resistant	NULL
colonies	NULL
.	NULL

ERK2	NULL
kinase	NULL
assays	NULL
BCL-6	NULL
GST	NULL
fusion	NULL
proteins	NULL
were	NULL
purified	NULL
using	NULL
glutathione-Sepharose	NULL
beads	NULL
as	NULL
suggested	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
.	NULL

Recombinant	NULL
ERK2	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
suggested	NULL
by	NULL
the	NULL
manufacturer	NULL
using	NULL
purified	NULL
wild-type	NULL
and	NULL
mutant	NULL
GST	NULL
fusion	NULL
proteins	NULL
as	NULL
substrates	NULL
.	NULL

In	NULL
Regulation	NULL
of	NULL
BCL-6	NULL
by	NULL
antigen	NULL
receptor	NULL
signaling	NULL
solid-phase	NULL
ERK2	NULL
kinase	NULL
assays	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
ice-cold	NULL
lysis	NULL
buffer	NULL
(	NULL
50	NULL
mm	NULL
Tris	NULL
at	NULL
pH	NULL
7.5	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
150	NULL
mm	NULL
NaCl	NULL
,	NULL
100	NULL
mm	NULL
NaF	NULL
,	NULL
5	NULL
um	NULL
ZnCl	NULL
;	NULL
,	NULL
,	NULL
1	NULL
mM	NULL
Na	NULL
,	NULL
;	NULL
VO	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
EGTA	NULL
,	NULL
2	NULL
mm	NULL
PMSF	NULL
,	NULL
1	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
1	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
and	NULL
1	NULL
ug/ml	NULL
pepstatin	NULL
)	NULL
and	NULL
centrifuged	NULL
at	NULL
100,000g	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
supernatant	NULL
(	NULL
250-500	NULL
ug	NULL
cellular	NULL
protein	NULL
)	NULL
was	NULL
then	NULL
im	NULL
munoprecipitated	NULL
using	NULL
anti-ERK2	NULL
antibodies	NULL
(	NULL
C-14	NULL
)	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
CL-4B	NULL
.	NULL

Beads	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
lysis	NULL
buffer	NULL
and	NULL
once	NULL
with	NULL
kinase	NULL
buffer	NULL
(	NULL
50	NULL
mm	NULL
Tris	NULL
at	NULL
pH	NULL
7.5	NULL
,	NULL
10	NULL
mm	NULL
MnCl	NULL
;	NULL
,	NULL
5	NULL
mm	NULL
MgCl	NULL
,	NULL
)	NULL
.	NULL

Reactions	NULL
were	NULL
initiated	NULL
by	NULL
adding	NULL
50	NULL
ul	NULL
kinase	NULL
buffer	NULL
containing	NULL
substrate	NULL
MBP	NULL
,	NULL
5	NULL
um	NULL
ATP	NULL
,	NULL
and	NULL
5	NULL
uCi	NULL
[	NULL
y-°PJATP	NULL
.	NULL

After	NULL
15	NULL
min	NULL
at	NULL
37°C	NULL
,	NULL
reactions	NULL
were	NULL
terminated	NULL
by	NULL
adding	NULL
2x	NULL
SDS-PAGE	NULL
sample	NULL
buffer	NULL
.	NULL

Samples	NULL
were	NULL
electrophoresed	NULL
on	NULL
15	NULL
%	NULL
SDS-polyacrylamide	NULL
gels	NULL
which	NULL
were	NULL
then	NULL
dried	NULL
and	NULL
analyzed	NULL
by	NULL
autoradiography	NULL
.	NULL

Cell	NULL
transfection	NULL
293T	NULL
cells	NULL
,	NULL
grown	NULL
in	NULL
DMEM	NULL
,	NULL
10	NULL
%	NULL
FBS	NULL
,	NULL
were	NULL
transfected	NULL
transiently	NULL
with	NULL
various	NULL
DN	NULL
A	NULL
vectors	NULL
using	NULL
standard	NULL
calcium	NULL
phosphate	NULL
precipitation	NULL
methods	NULL
.	NULL

Ramos	NULL
cells	NULL
,	NULL
grown	NULL
in	NULL
IMDM	NULL
,	NULL
10	NULL
%	NULL
FBS	NULL
,	NULL
were	NULL
transfected	NULL
stably	NULL
with	NULL
the	NULL
plasm	NULL
id	NULL
pHeBo-MT-HA-BCL-6	NULL
,	NULL
pHeBo-MT-HA-BCL-6a	NULL
)	NULL
,3533,343	NULL
and	NULL
the	NULL
deletion-mutant	NULL
construct	NULL
pHeBo-MT-HA-BCL-6ZF	NULL
by	NULL
electroporation	NULL
followed	NULL
by	NULL
selection	NULL
in	NULL
hygromycin	NULL
B	NULL
(	NULL
400	NULL
ug/ml	NULL
)	NULL
.	NULL

HA-bel-6	NULL
gene	NULL
expression	NULL
under	NULL
control	NULL
of	NULL
the	NULL
metallothionein	NULL
(	NULL
MT	NULL
)	NULL
promoter	NULL
were	NULL
induced	NULL
by	NULL
adding	NULL
1	NULL
um	NULL
of	NULL
CdCl	NULL
,	NULL
.	NULL

Northern	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
Total	NULL
RNA	NULL
were	NULL
isolated	NULL
from	NULL
cells	NULL
by	NULL
using	NULL
Trizol-reagents	NULL
(	NULL
GIBCO-BRL	NULL
)	NULL
and	NULL
equal	NULL
amounts	NULL
of	NULL
RN	NULL
A	NULL
were	NULL
separated	NULL
on	NULL
1	NULL
%	NULL
formaldehyde-agarose	NULL
gel	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
standard	NULL
methods	NULL
with	NULL
full-length	NULL
bel-6	NULL
cDNA	NULL
as	NULL
probes	NULL
and	NULL
normalized	NULL
by	NULL
GAPDH	NULL
hybridization	NULL
.	NULL

Whole-cell	NULL
lysates	NULL
were	NULL
prepared	NULL
by	NULL
lysing	NULL
cells	NULL
in	NULL
RIPA	NULL
buffer	NULL
with	NULL
2	NULL
mM	NULL
PMSF	NULL
,	NULL
1	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
1	NULL
ug/ml	NULL
of	NULL
leupeptin	NULL
,	NULL
1	NULL
ug/ml	NULL
pep-statin	NULL
,	NULL
1	NULL
mM	NULL
Na	NULL
,	NULL
VO	NULL
,	NULL
,	NULL
5	NULL
mM	NULL
NaF	NULL
,	NULL
and	NULL
10	NULL
mm	NULL
B-glycerophos-phate	NULL
.	NULL

For	NULL
transient	NULL
transfectants	NULL
,	NULL
protein	NULL
amounts	NULL
loaded	NULL
on	NULL
gel	NULL
were	NULL
normalized	NULL
by	NULL
transfection	NULL
efficiency	NULL
(	NULL
B-gal	NULL
activity	NULL
)	NULL
.	NULL

For	NULL
Ramos	NULL
cells	NULL
and	NULL
their	NULL
stable	NULL
transfectants	NULL
(	NULL
untreated	NULL
or	NULL
treated	NULL
)	NULL
,	NULL
equal	NULL
amounts	NULL
of	NULL
protein	NULL
were	NULL
analyzed	NULL
by	NULL
8	NULL
%	NULL
or	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
subsequently	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
using	NULL
anti-BCL-6	NULL
(	NULL
N-70-6	NULL
)	NULL
,	NULL
anti-ERK2	NULL
(	NULL
C-14	NULL
)	NULL
,	NULL
or	NULL
anti-HA	NULL
(	NULL
12CA5	NULL
)	NULL
antibodies	NULL
at	NULL
1:3000	NULL
,	NULL
1:1000	NULL
,	NULL
or	NULL
1:500	NULL
dilutions	NULL
.	NULL

The	NULL
results	NULL
were	NULL
visualized	NULL
by	NULL
ECL	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
ubiquitination	NULL
assay	NULL
293T	NULL
cells	NULL
were	NULL
transfected	NULL
transiently	NULL
with	NULL
pMT2T-BCL-6	NULL
,	NULL
His	NULL
,	NULL
-ubiquitin-CMV	NULL
,	NULL
and	NULL
MEK-2E-CMV	NULL
vectors	NULL
as	NULL
indicated	NULL
.	NULL

MG132	NULL
(	NULL
50	NULL
um	NULL
)	NULL
was	NULL
added	NULL
8	NULL
hr	NULL
after	NULL
transfection	NULL
.	NULL

The	NULL
total	NULL
amount	NULL
of	NULL
transfected	NULL
DNA	NULL
was	NULL
kept	NULL
constant	NULL
in	NULL
all	NULL
experiments	NULL
by	NULL
adding	NULL
empty	NULL
vector	NULL
.	NULL

Twenty-four	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
RIPA	NULL
buffer	NULL
with	NULL
10	NULL
mm	NULL
N-ethylma-leimide	NULL
and	NULL
various	NULL
protease	NULL
inhibitors	NULL
as	NULL
described	NULL
(	NULL
Pagano	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
lysates	NULL
were	NULL
then	NULL
im	NULL
munoprecipitated	NULL
using	NULL
anti-BCL-6	NULL
antibodies	NULL
.	NULL

The	NULL
imm	NULL
unoprecipitates	NULL
were	NULL
loaded	NULL
on	NULL
6	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
processed	NULL
for	NULL
Western	NULL
blot	NULL
analysis	NULL
using	NULL
the	NULL
anti-ubiquitin	NULL
antibodies	NULL
(	NULL
Zymed	NULL
)	NULL
at	NULL
1:1000	NULL
dilution	NULL
as	NULL
described	NULL
(	NULL
Avantaggiati	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Pulse-chase	NULL
labeling	NULL
experim	NULL
ent	NULL
Ramos	NULL
cells	NULL
(	NULL
12	NULL
x	NULL
10	NULL
``	NULL
)	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
,	NULL
washed	NULL
in	NULL
PBS	NULL
,	NULL
resuspended	NULL
in	NULL
100	NULL
ml	NULL
of	NULL
DMEM	NULL
without	NULL
methionine	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
1959	NULL
Niu	NULL
et	NULL
al	NULL
.	NULL

and	NULL
cysteine	NULL
(	NULL
GIBCO-BRL	NULL
)	NULL
,	NULL
and	NULL
starved	NULL
for	NULL
60	NULL
min	NULL
.	NULL

nine	NULL
and	NULL
[	NULL
SSS	NULL
]	NULL
cysteine	NULL
(	NULL
3	NULL
mCi	NULL
;	NULL
ICN	NULL
)	NULL
were	NULL
added	NULL
and	NULL
pulse-la-beled	NULL
for	NULL
60	NULL
min	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
anti-IgM	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Cold	NULL
methionine	NULL
and	NULL
cysteine	NULL
were	NULL
then	NULL
added	NULL
to	NULL
final	NULL
concentrations	NULL
of	NULL
150	NULL
ug/m1	NULL
.	NULL

Cells	NULL
were	NULL
collected	NULL
and	NULL
lysed	NULL
in	NULL
RIPA	NULL
buffer	NULL
with	NULL
proteinase	NULL
and	NULL
phosphatase	NULL
inhibitors	NULL
.	NULL

The	NULL
cell	NULL
ex-tracts	NULL
,	NULL
adjusted	NULL
for	NULL
equal	NULL
cpm	NULL
,	NULL
were	NULL
imm	NULL
with	NULL
anti-BCL-6	NULL
antibodies	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
followed	NULL
by	NULL
autoradiography	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
D.	NULL
Templeton	NULL
for	NULL
a	NULL
gift	NULL
of	NULL
the	NULL
MEK-2E-EE-CMV	NULL
and	NULL
MEK-EE-CMV	NULL
plasmids	NULL
;	NULL
TK	NULL
.	NULL

Kim	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
for	NULL
the	NULL
His	NULL
,	NULL
-ubiquitin-CMV	NULL
plasmid	NULL
;	NULL
S.W	NULL
.	NULL

Rogers	NULL
,	NULL
P.	NULL
Zhang	NULL
,	NULL
and	NULL
L.	NULL
Liao	NULL
for	NULL
help	NULL
with	NULL
the	NULL
use	NULL
of	NULL
the	NULL
PEST-FIND	NULL
program	NULL
;	NULL
and	NULL
S.	NULL
Chellapan	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
grant	NULL
CA-37295	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
USC	NULL
section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

References	NULL
Albagli	NULL
,	NULL
O.	NULL
,	NULL
P.	NULL
Dhordain	NULL
,	NULL
C.	NULL
Deweindt	NULL
,	NULL
G.	NULL
Lecocq	NULL
,	NULL
and	NULL
D.	NULL
Leprince	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
BTB/POZ	NULL
domain	NULL
:	NULL
A	NULL
new	NULL
protein-protein	NULL
interaction	NULL
motif	NULL
common	NULL
to	NULL
DNA-	NULL
and	NULL
actin-binding	NULL
proteins	NULL
.	NULL

Cell	NULL
Growth	NULL
&	NULL
Differ	NULL
.	NULL

6:11193-1198	NULL
.	NULL

Alberola-lMla	NULL
,	NULL
J.	NULL
,	NULL
S.	NULL
Takaki	NULL
,	NULL
J.D	NULL
.	NULL

Kerner	NULL
,	NULL
and	NULL
R.M	NULL
.	NULL

Perlmutter	NULL
.	NULL

1997	NULL
.	NULL

Differential	NULL
signaling	NULL
by	NULL
lymphocyte	NULL
antigen	NULL
receptors	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

151	NULL
125-154	NULL
.	NULL

Allman	NULL
,	NULL
D.	NULL
,	NULL
A.	NULL
Jain	NULL
,	NULL
A.	NULL
Dent	NULL
,	NULL
R.R	NULL
.	NULL

Maile	NULL
,	NULL
T.	NULL
Selvaggi	NULL
,	NULL
M.R	NULL
.	NULL

Ke-hry	NULL
,	NULL
and	NULL
LM	NULL
.	NULL

Staudt	NULL
.	NULL

1996	NULL
.	NULL

BCL-6	NULL
expression	NULL
during	NULL
B-cell	NULL
activation	NULL
.	NULL

Blood	NULL
87:5257-5268	NULL
.	NULL

Avantaggiati	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Carbone	NULL
,	NULL
A.	NULL
Graessman	NULL
,	NULL
Y.	NULL
Nakatani	NULL
,	NULL
B.	NULL
Howard	NULL
,	NULL
and	NULL
A.	NULL
Levine	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
SV40	NULL
large	NULL
T	NULL
antigen	NULL
and	NULL
adenovirus	NULL
E1A	NULL
oncoproteins	NULL
interact	NULL
with	NULL
distinct	NULL
isoforms	NULL
of	NULL
the	NULL
transcriptional	NULL
co-activator	NULL
p300	NULL
.	NULL

EMBO	NULL
J	NULL
15	NULL
:	NULL
2236-2248	NULL
.	NULL

Bardwell	NULL
,	NULL
V.J	NULL
.	NULL

and	NULL
R.	NULL
Treisman	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
POZ	NULL
domain	NULL
:	NULL
A	NULL
conserved	NULL
protein-protein	NULL
interaction	NULL
motif	NULL
.	NULL

Genes	NULL
&	NULL
Dev	NULL
.	NULL

8	NULL
:	NULL
1664-1677	NULL
.	NULL

Baron	NULL
,	NULL
BW	NULL
.	NULL

,	NULL
G.	NULL
Nucifora	NULL
,	NULL
N.	NULL
McCabe	NULL
,	NULL
R.	NULL
Espinosa	NULL
,	NULL
B.M	NULL
.	NULL

Le	NULL
,	NULL
and	NULL
T.W	NULL
.	NULL

McKeithan	NULL
.	NULL

1993	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
gene	NULL
associated	NULL
with	NULL
the	NULL
-	NULL
recurring	NULL
-	NULL
chromosomal	NULL
_	NULL
translocations	NULL
t1G	NULL
;	NULL
14	NULL
)	NULL
@	NULL
27	NULL
;	NULL
q32	NULL
)	NULL
and	NULL
t	NULL
(	NULL
3	NULL
;	NULL
22	NULL
)	NULL
q27	NULL
;	NULL
q11	NULL
)	NULL
in	NULL
B-cell	NULL
lymphomas	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

901	NULL
5262-5266	NULL
.	NULL

Bastard	NULL
,	NULL
C.	NULL
,	NULL
C.	NULL
Deweindt	NULL
,	NULL
J.P.	NULL
Kerckaert	NULL
,	NULL
B.	NULL
Lenormand	NULL
,	NULL
A.	NULL
Rossi	NULL
,	NULL
F.	NULL
Pezzella	NULL
,	NULL
C.	NULL
Fruchart	NULL
,	NULL
C.	NULL
Duval	NULL
,	NULL
M.	NULL
Monconduit	NULL
,	NULL
and	NULL
H.	NULL
Tilly	NULL
.	NULL

1994	NULL
.	NULL

LAZ3	NULL
rearrangements	NULL
in	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
:	NULL
Correlation	NULL
with	NULL
histology	NULL
,	NULL
immunophenotype	NULL
,	NULL
karyotype	NULL
,	NULL
and	NULL
clinical	NULL
outcome	NULL
in	NULL
217	NULL
patients	NULL
.	NULL

Blood	NULL
83	NULL
:	NULL
2423-2427	NULL
.	NULL

Cambier	NULL
,	NULL
J.C.	NULL
1997	NULL
.	NULL

Positive	NULL
and	NULL
negative	NULL
signal	NULL
co-operativity	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
:	NULL
The	NULL
BCR	NULL
,	NULL
Fc	NULL
gamma	NULL
RIB	NULL
,	NULL
CR2	NULL
para-digm	NULL
.	NULL

Biochem	NULL
.	NULL

Soc	NULL
.	NULL

Trans	NULL
.	NULL

251	NULL
441-445	NULL
.	NULL

Cattoretti	NULL
,	NULL
G.	NULL
,	NULL
C.C	NULL
.	NULL

Chang	NULL
,	NULL
K.	NULL
Cechova	NULL
,	NULL
J.	NULL
Zhang	NULL
,	NULL
BH	NULL
.	NULL

Ye	NULL
,	NULL
B.	NULL
Falini	NULL
,	NULL
D.C.	NULL
Louie	NULL
,	NULL
K.	NULL
Offit	NULL
,	NULL
R.S	NULL
.	NULL

Chaganti	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1995	NULL
.	NULL

BCL-6	NULL
protein	NULL
is	NULL
expressed	NULL
in	NULL
germinal-center	NULL
B	NULL
cells	NULL
.	NULL

Blood	NULL
86	NULL
:	NULL
45-53	NULL
.	NULL

Cattoretti	NULL
,	NULL
G.	NULL
,	NULL
J.	NULL
Zhang	NULL
,	NULL
A.M.	NULL
Cleary	NULL
,	NULL
S.	NULL
Lederman	NULL
,	NULL
G.	NULL
Gaidano	NULL
,	NULL
A.	NULL
Carbone	NULL
,	NULL
R.S.K	NULL
.	NULL

Chaganti	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1997	NULL
.	NULL

Downregulation	NULL
of	NULL
BCL-6	NULL
gene	NULL
expression	NULL
by	NULL
CD40	NULL
and	NULL
EBV	NULL
latent	NULL
membrane	NULL
protein-1	NULL
(	NULL
LMP1	NULL
)	NULL
and	NULL
its	NULL
block	NULL
in	NULL
lym	NULL
1960	NULL
GENES	NULL
&	NULL
DEVELOPMENT	NULL
phoma	NULL
carrying	NULL
BCL-6	NULL
rearrangements	NULL
.	NULL

(	NULL
Suppl	NULL
.	NULL

I	NULL
)	NULL
Blood	NULL
90	NULL
:	NULL
p175a	NULL
.	NULL

Chang	NULL
,	NULL
C.C	NULL
.	NULL

,	NULL
B.H	NULL
.	NULL

Ye	NULL
,	NULL
R.S	NULL
.	NULL

Chaganti	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1996	NULL
.	NULL

BCL-6	NULL
,	NULL
a	NULL
POZ/zinc-finger	NULL
protein	NULL
,	NULL
is	NULL
a	NULL
sequence-specific	NULL
transcriptional	NULL
repressor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

9316947-6952	NULL
.	NULL

Chardin	NULL
,	NULL
P.	NULL
,	NULL
G.	NULL
Courtois	NULL
,	NULL
M.G	NULL
.	NULL

Mattei	NULL
,	NULL
and	NULL
S.	NULL
Gisselbrecht	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
KUP	NULL
gene	NULL
,	NULL
located	NULL
on	NULL
human	NULL
chromosome	NULL
14	NULL
,	NULL
encodes	NULL
a	NULL
protein	NULL
with	NULL
two	NULL
distant	NULL
zinc	NULL
fingers	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19	NULL
:	NULL
1431-1436	NULL
.	NULL

Chen	NULL
,	NULL
Z.	NULL
,	NULL
N.J	NULL
.	NULL

Brand	NULL
,	NULL
A.	NULL
Chen	NULL
,	NULL
S.J	NULL
.	NULL

Chen	NULL
,	NULL
J.H	NULL
.	NULL

Tong	NULL
,	NULL
Z.Y	NULL
.	NULL

Wang	NULL
,	NULL
S.	NULL
Waxman	NULL
,	NULL
and	NULL
A.	NULL
Zelent	NULL
.	NULL

1993	NULL
.	NULL

Fusion	NULL
between	NULL
a	NULL
novel	NULL
Kruppel-like	NULL
zinc	NULL
finger	NULL
gene	NULL
and	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor-alpha	NULL
locus	NULL
due	NULL
to	NULL
a	NULL
variant	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
associated	NULL
with	NULL
-	NULL
acute	NULL
promyelocytic	NULL
-	NULL
leukaemia	NULL
.	NULL

EMBO	NULL
_	NULL
J	NULL
12	NULL
:	NULL
1161-1167	NULL
.	NULL

Chen	NULL
,	NULL
Z.	NULL
,	NULL
F.	NULL
Guidez	NULL
,	NULL
P.	NULL
Rousselot	NULL
,	NULL
A.	NULL
Agadir	NULL
,	NULL
S.J	NULL
.	NULL

Chen	NULL
,	NULL
Z.Y	NULL
.	NULL

Wang	NULL
,	NULL
L.	NULL
Degos	NULL
,	NULL
A.	NULL
Zelent	NULL
,	NULL
S.	NULL
Waxman	NULL
,	NULL
and	NULL
C.	NULL
Chomienne	NULL
.	NULL

1994	NULL
.	NULL

PLZF-RAR	NULL
alpha	NULL
fusion	NULL
proteins	NULL
generated	NULL
from	NULL
the	NULL
variant	NULL
t	NULL
(	NULL
11	NULL
;	NULL
17	NULL
)	NULL
@	NULL
@	NULL
23	NULL
;	NULL
q21	NULL
)	NULL
translocation	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
inhibit	NULL
ligand-dependent	NULL
transactivation	NULL
of	NULL
wild-type	NULL
retinoic	NULL
acid	NULL
receptors	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

91	NULL
:	NULL
1178-1182	NULL
.	NULL

Chen	NULL
,	NULL
W.	NULL
,	NULL
S.	NULL
ida	NULL
,	NULL
D.C.	NULL
Louie	NULL
,	NULL
R.	NULL
Dalla-Favera	NULL
,	NULL
and	NULL
R.S.K	NULL
.	NULL

Chaganti	NULL
.	NULL

1998	NULL
.	NULL

Heterologous	NULL
promoters	NULL
fused	NULL
to	NULL
BCL-6	NULL
by	NULL
chromosomal	NULL
translocations	NULL
affecting	NULL
band	NULL
3q27	NULL
cause	NULL
its	NULL
deregulated	NULL
expression	NULL
during	NULL
B-cell	NULL
differentiation	NULL
.	NULL

Blood	NULL
91	NULL
:	NULL
603-607	NULL
.	NULL

Dalla-Favera	NULL
,	NULL
R.	NULL
,	NULL
BH	NULL
.	NULL

Ye	NULL
,	NULL
G.	NULL
Cattoretti	NULL
,	NULL
F.	NULL
Lo	NULL
Coco	NULL
,	NULL
C.C	NULL
.	NULL

Chang	NULL
,	NULL
J.	NULL
Zhang	NULL
,	NULL
A.	NULL
Migliazza	NULL
,	NULL
K.	NULL
Cechova	NULL
,	NULL
H.	NULL
Niu	NULL
,	NULL
S.	NULL
Chaganti	NULL
,	NULL
W.	NULL
Chen	NULL
,	NULL
D.C.	NULL
Louie	NULL
,	NULL
K.	NULL
Offit	NULL
,	NULL
and	NULL
R.S	NULL
.	NULL

Chaganti	NULL
.	NULL

1996	NULL
.	NULL

BCL-6	NULL
in	NULL
diffuse	NULL
large-cell	NULL
lymphomas	NULL
.	NULL

In	NULL
Important	NULL
advances	NULL
in	NULL
oncology	NULL
(	NULL
ed	NULL
.	NULL

V.T	NULL
.	NULL

DeVita	NULL
,	NULL
S.	NULL
Hellman	NULL
,	NULL
and	NULL
S.A.	NULL
Rosenberg	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

139-148	NULL
.	NULL

Lippincott-Raven	NULL
Publishers	NULL
,	NULL
Philadelphia	NULL
,	NULL
PA.	NULL
Dent	NULL
,	NULL
A.L	NULL
.	NULL

,	NULL
A.L	NULL
.	NULL

Shaffer	NULL
,	NULL
X.	NULL
Yu	NULL
,	NULL
D.	NULL
Allman	NULL
,	NULL
and	NULL
LM	NULL
.	NULL

Staudt	NULL
.	NULL

1997	NULL
.	NULL

Control	NULL
of	NULL
inflammation	NULL
,	NULL
cytokine	NULL
expression	NULL
,	NULL
and	NULL
germinal	NULL
center	NULL
formation	NULL
by	NULL
BCL-6	NULL
.	NULL

Science	NULL
276:589-592	NULL
.	NULL

Deweindt	NULL
,	NULL
C.	NULL
,	NULL
O.	NULL
Albagli	NULL
,	NULL
F.	NULL
Bernardin	NULL
,	NULL
P.	NULL
Dhordain	NULL
,	NULL
S.	NULL
Quief	NULL
,	NULL
D.	NULL
Lantoine	NULL
,	NULL
J.P.	NULL
Kerckaert	NULL
,	NULL
and	NULL
D.	NULL
Leprince	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
LAZ3/	NULL
BCL6	NULL
oncogene	NULL
encodes	NULL
a	NULL
sequence-specific	NULL
transcriptional	NULL
inhibitor	NULL
:	NULL
A	NULL
novel	NULL
function	NULL
for	NULL
the	NULL
BTB/POZ	NULL
domain	NULL
as	NULL
an	NULL
autonomous	NULL
repressing	NULL
domain	NULL
.	NULL

Cell	NULL
Growth	NULL
&	NULL
Differ	NULL
.	NULL

6	NULL
:	NULL
1495-1503	NULL
.	NULL

DiBello	NULL
,	NULL
P.R	NULL
.	NULL

,	NULL
D.A	NULL
.	NULL

Withers	NULL
,	NULL
C.A	NULL
.	NULL

Bayer	NULL
,	NULL
JW	NULL
.	NULL

Fristrom	NULL
,	NULL
and	NULL
G.M	NULL
.	NULL

Guild	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
Drosophila	NULL
Broad-Com	NULL
plex	NULL
encodes	NULL
a	NULL
fam	NULL
ily	NULL
of	NULL
related	NULL
proteins	NULL
containing	NULL
zinc	NULL
fingers	NULL
.	NULL

Genetics	NULL
129	NULL
:	NULL
385-397	NULL
.	NULL

Dudley	NULL
,	NULL
D.T	NULL
.	NULL

,	NULL
L.	NULL
Pang	NULL
,	NULL
S.J	NULL
.	NULL

Decker	NULL
,	NULL
A.J	NULL
.	NULL

Bridges	NULL
,	NULL
and	NULL
A.R	NULL
.	NULL

Saltiel	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
synthetic	NULL
inhibitor	NULL
of	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
cascade	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

921	NULL
7686-7689	NULL
.	NULL

Emery	NULL
,	NULL
LF	NULL
.	NULL

,	NULL
V.	NULL
Bedian	NULL
,	NULL
and	NULL
G.M	NULL
.	NULL

Guild	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
expression	NULL
of	NULL
Broad-Complex	NULL
transcription	NULL
factors	NULL
may	NULL
forecast	NULL
tissue-specific	NULL
developmental	NULL
fates	NULL
during	NULL
Drosophila	NULL
metamorphosis	NULL
.	NULL

Developm	NULL
ent	NULL
120	NULL
:	NULL
3275-3287	NULL
.	NULL

Fukada	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Hibi	NULL
,	NULL
Y.	NULL
Yamanaka	NULL
,	NULL
M.	NULL
Takahashi-Tezuka	NULL
,	NULL
Y.	NULL
Fujitani	NULL
,	NULL
T.	NULL
Yamaguchi	NULL
,	NULL
K.	NULL
Nakajima	NULL
,	NULL
and	NULL
T.	NULL
Hirano	NULL
.	NULL

1996	NULL
.	NULL

Two	NULL
signals	NULL
are	NULL
necessary	NULL
for	NULL
cell	NULL
proliferation	NULL
induced	NULL
by	NULL
a	NULL
cytokine	NULL
receptor	NULL
gp130	NULL
:	NULL
Involvement	NULL
of	NULL
STAT3	NULL
in	NULL
anti-apoptosis	NULL
.	NULL

Imm	NULL
unity	NULL
51449-460	NULL
.	NULL

Gaidano	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
Carbone	NULL
,	NULL
C.	NULL
Pastore	NULL
,	NULL
D.	NULL
Capello	NULL
,	NULL
A.	NULL
Migliazza	NULL
,	NULL
A.	NULL
Gloghini	NULL
,	NULL
S.	NULL
Roncella	NULL
,	NULL
M.	NULL
Ferrarini	NULL
,	NULL
G.	NULL
Saglio	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1997	NULL
.	NULL

Frequent	NULL
mutation	NULL
of	NULL
the	NULL
5	NULL
'	NULL
noncoding	NULL
region	NULL
of	NULL
the	NULL
BCL-6	NULL
gene	NULL
in	NULL
acquired	NULL
immunodeficiency	NULL
syn-drome-related	NULL
non-Hodgkin	NULL
's	NULL
lymphomas	NULL
.	NULL

Blood	NULL
89	NULL
:	NULL
3762	NULL
.	NULL

Gold	NULL
,	NULL
M.R	NULL
.	NULL

and	NULL
L.	NULL
Matsuuchi	NULL
.	NULL

1995	NULL
.	NULL

Signal	NULL
transduction	NULL
by	NULL
the	NULL
antigen	NULL
receptors	NULL
of	NULL
B	NULL
and	NULL
T	NULL
lymphocytes	NULL
.	NULL

Int	NULL
.	NULL

Rev	NULL
.	NULL

Cytol	NULL
.	NULL

157	NULL
:	NULL
181-276	NULL
.	NULL

Gold	NULL
,	NULL
MR.	NULL
,	NULL
J.S	NULL
.	NULL

Sanghera	NULL
,	NULL
J.	NULL
Stewart	NULL
,	NULL
and	NULL
S.L	NULL
.	NULL

Pelech	NULL
.	NULL

1992	NULL
.	NULL

Selective	NULL
activation	NULL
of	NULL
p42	NULL
mitogen-activated	NULL
protein	NULL
(	NULL
MAP	NULL
)	NULL
kinase	NULL
in	NULL
murine	NULL
B	NULL
lymphoma	NULL
cell	NULL
lines	NULL
by	NULL
membrane	NULL
im-munoglobulin	NULL
cross-linking	NULL
.	NULL

Evidence	NULL
for	NULL
protein	NULL
kinase	NULL
C-independent	NULL
and	NULL
-dependent	NULL
mechanisms	NULL
of	NULL
activation	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

287:269-276	NULL
.	NULL

Harrison	NULL
,	NULL
S.D	NULL
.	NULL

and	NULL
A.A.	NULL
Travers	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
Tramtrack	NULL
gene	NULL
encodes	NULL
a	NULL
Drosophila	NULL
finger	NULL
protein	NULL
that	NULL
interacts	NULL
with	NULL
the	NULL
ftz	NULL
transcriptional	NULL
regulatory	NULL
region	NULL
and	NULL
shows	NULL
a	NULL
novel	NULL
embryonic	NULL
expression	NULL
pattern	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9	NULL
:	NULL
207-216	NULL
.	NULL

Hochstrasser	NULL
,	NULL
M.	NULL
1996	NULL
.	NULL

Ubiquitin-dependent	NULL
protein	NULL
degradation	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Genet	NULL
.	NULL

30	NULL
:	NULL
405-439	NULL
.	NULL

Kerckaert	NULL
,	NULL
J.P.	NULL
,	NULL
C.	NULL
Deweindt	NULL
,	NULL
H.	NULL
Tilly	NULL
,	NULL
S.	NULL
Quief	NULL
,	NULL
G.	NULL
Lecocq	NULL
,	NULL
and	NULL
C.	NULL
Bastard	NULL
.	NULL

1993	NULL
.	NULL

LAZ3	NULL
,	NULL
a	NULL
novel	NULL
zinc-finger	NULL
encoding	NULL
gene	NULL
,	NULL
is	NULL
disrupted	NULL
by	NULL
recurring	NULL
chromosome	NULL
3q27	NULL
translocations	NULL
in	NULL
human	NULL
lymphomas	NULL
.	NULL

Nature	NULL
Genet	NULL
.	NULL

5166-70	NULL
.	NULL

Kim	NULL
,	NULL
TK	NULL
.	NULL

and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1996	NULL
.	NULL

Regulation	NULL
of	NULL
interferon-gamma-activated	NULL
STAT	NULL
1	NULL
by	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
.	NULL

Science	NULL
27311717-1719	NULL
.	NULL

Koonin	NULL
,	NULL
E.V	NULL
.	NULL

,	NULL
T.G	NULL
.	NULL

Senkevich	NULL
,	NULL
and	NULL
V.I	NULL
Chernos	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
family	NULL
of	NULL
DNA	NULL
virus	NULL
genes	NULL
that	NULL
consists	NULL
of	NULL
fused	NULL
portions	NULL
of	NULL
unrelated	NULL
cellular	NULL
genes	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

171213-214	NULL
.	NULL

Li	NULL
,	NULL
S.	NULL
,	NULL
Y.	NULL
Li	NULL
,	NULL
R.W	NULL
.	NULL

Carthew	NULL
,	NULL
and	NULL
Z.-C.	NULL
Lai	NULL
.	NULL

1997	NULL
.	NULL

Photoreceptor	NULL
cell	NULL
differentiation	NULL
requires	NULL
regulated	NULL
proteolysis	NULL
of	NULL
the	NULL
transcriptional	NULL
repressor	NULL
Tram	NULL
track	NULL
.	NULL

Cell	NULL
90	NULL
:	NULL
469-478	NULL
.	NULL

LoCoco	NULL
,	NULL
C.F	NULL
.	NULL

,	NULL
BH	NULL
.	NULL

Ye	NULL
,	NULL
F.	NULL
Lista	NULL
,	NULL
P.	NULL
Corradini	NULL
,	NULL
K.	NULL
Offit	NULL
,	NULL
D.M	NULL
.	NULL

Knowles	NULL
,	NULL
R.S	NULL
.	NULL

Chaganti	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1994	NULL
.	NULL

Rearrangements	NULL
of	NULL
the	NULL
BCL6	NULL
gene	NULL
in	NULL
diffuse	NULL
large	NULL
cell	NULL
non-Hodgkin	NULL
's	NULL
lymphoma	NULL
.	NULL

Blood	NULL
83:1757-1759	NULL
.	NULL

MacLennan	NULL
,	NULL
LC	NULL
.	NULL

1994	NULL
.	NULL

Germinal	NULL
centers	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Im	NULL
m	NULL
unol	NULL
.	NULL

12	NULL
:	NULL
117-139	NULL
.	NULL

Migliazza	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
Martinotti	NULL
,	NULL
W.	NULL
Chen	NULL
,	NULL
C.	NULL
Fusco	NULL
,	NULL
B.H	NULL
.	NULL

Ye	NULL
,	NULL
D.M	NULL
.	NULL

Knowles	NULL
,	NULL
K.	NULL
Offit	NULL
,	NULL
R.S	NULL
.	NULL

Chaganti	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1995	NULL
.	NULL

Frequent	NULL
somatic	NULL
hypermutation	NULL
of	NULL
the	NULL
5	NULL
'	NULL
noncoding	NULL
region	NULL
of	NULL
the	NULL
BCL6	NULL
gene	NULL
in	NULL
B-cell	NULL
lymphoma	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

92	NULL
:	NULL
12520-12524	NULL
.	NULL

Miki	NULL
,	NULL
T.	NULL
,	NULL
N.	NULL
Kawamata	NULL
,	NULL
S.	NULL
Hirosawa	NULL
,	NULL
and	NULL
N.	NULL
Aoki	NULL
.	NULL

1994	NULL
.	NULL

Gene	NULL
involved	NULL
in	NULL
the	NULL
3q27	NULL
translocation	NULL
associated	NULL
with	NULL
B-cell	NULL
lymphoma	NULL
,	NULL
BCLS5	NULL
,	NULL
encodes	NULL
a	NULL
Kruppel-like	NULL
zinc-finger	NULL
pro-tein	NULL
.	NULL

Blood	NULL
83:26-32	NULL
.	NULL

Minami	NULL
,	NULL
Y.	NULL
,	NULL
I.	NULL
Oishi	NULL
,	NULL
Z.J	NULL
.	NULL

Liu	NULL
,	NULL
S.	NULL
Nakagawa	NULL
,	NULL
T.	NULL
Miyazaki	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1994	NULL
.	NULL

Signal	NULL
transduction	NULL
mediated	NULL
by	NULL
the	NULL
reconstituted	NULL
IL-2	NULL
receptor	NULL
.	NULL

Evidence	NULL
for	NULL
a	NULL
cell	NULL
type-specific	NULL
function	NULL
of	NULL
IL-2	NULL
receptor	NULL
beta-chain	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

152:5680-5690	NULL
.	NULL

Moriyama	NULL
,	NULL
M.	NULL
,	NULL
T.	NULL
Yamochi	NULL
,	NULL
K.	NULL
Semba	NULL
,	NULL
T.	NULL
Akiyama	NULL
,	NULL
and	NULL
S.	NULL
Mori	NULL
.	NULL

1997	NULL
.	NULL

BCL-6	NULL
is	NULL
phosphorylated	NULL
at	NULL
multiple	NULL
sites	NULL
in	NULL
its	NULL
serine-and	NULL
proline-clustered	NULL
region	NULL
by	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
(	NULL
MAPK	NULL
)	NULL
in	NULL
vivo	NULL
.	NULL

Oncogene	NULL
141	NULL
2465-2474	NULL
.	NULL

Onizuka	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Moriyama	NULL
,	NULL
T.	NULL
Yamochi	NULL
,	NULL
T.	NULL
Kuroda	NULL
,	NULL
A.	NULL
Kazama	NULL
,	NULL
N.	NULL
Kanazawa	NULL
,	NULL
K.	NULL
Sato	NULL
,	NULL
T.	NULL
Kato	NULL
,	NULL
H.	NULL
Ota	NULL
,	NULL
and	NULL
S.	NULL
Mori	NULL
.	NULL

1995	NULL
.	NULL

BCL-6	NULL
gene	NULL
product	NULL
,	NULL
a	NULL
92-	NULL
to	NULL
98-kD	NULL
nuclear	NULL
phosphoprotein	NULL
,	NULL
is	NULL
highly	NULL
expressed	NULL
in	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
and	NULL
their	NULL
neo-plastic	NULL
counterparts	NULL
.	NULL

Blood	NULL
86	NULL
:	NULL
28-37	NULL
.	NULL

Otsuki	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Yano	NULL
,	NULL
H.M.	NULL
Clark	NULL
,	NULL
C.	NULL
Bastard	NULL
,	NULL
J.P.	NULL
Kerckaert	NULL
,	NULL
E.S	NULL
.	NULL

Jaffe	NULL
,	NULL
and	NULL
M.	NULL
Raffeld	NULL
.	NULL

1995	NULL
.	NULL

Analysis	NULL
of	NULL
LAZ3	NULL
(	NULL
BCL-6	NULL
)	NULL
status	NULL
in	NULL
B-cell	NULL
non-Hodgkin	NULL
's	NULL
lymphomas	NULL
:	NULL
Results	NULL
of	NULL
rearrangement	NULL
and	NULL
gene	NULL
expression	NULL
studies	NULL
and	NULL
a	NULL
mutational	NULL
analysis	NULL
of	NULL
coding	NULL
region	NULL
sequences	NULL
.	NULL

Blood	NULL
85	NULL
:	NULL
2877-2884	NULL
.	NULL

Pagano	NULL
,	NULL
M.	NULL
,	NULL
SW.	NULL
Tam	NULL
,	NULL
A.M.	NULL
Theodoras	NULL
,	NULL
P.	NULL
Beer-Romero	NULL
,	NULL
G.	NULL
Del	NULL
Sal	NULL
,	NULL
V.	NULL
Chau	NULL
,	NULL
P.R	NULL
.	NULL

Yew	NULL
,	NULL
G.F.	NULL
Draetta	NULL
,	NULL
and	NULL
M.	NULL
Rolfe	NULL
.	NULL

1995	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
in	NULL
regulating	NULL
abundance	NULL
of	NULL
the	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
p27	NULL
.	NULL

Science	NULL
269	NULL
:	NULL
682-685	NULL
.	NULL

Regulation	NULL
of	NULL
BCL-6	NULL
by	NULL
antigen	NULL
receptor	NULL
signaling	NULL
bella	NULL
,	NULL
V.J	NULL
.	NULL

,	NULL
O.J	NULL
.	NULL

Rando	NULL
,	NULL
A.L	NULL
.	NULL

Goldberg	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
ubiquitin-proteasome	NULL
pathway	NULL
is	NULL
required	NULL
for	NULL
processing	NULL
the	NULL
NF-kappa	NULL
B1	NULL
precursor	NULL
protein	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
NF-kappa	NULL
B	NULL
.	NULL

Cell	NULL
78	NULL
:	NULL
773-785	NULL
.	NULL

Pang	NULL
,	NULL
L.	NULL
,	NULL
T.	NULL
Sawada	NULL
,	NULL
S.J	NULL
.	NULL

Decker	NULL
,	NULL
and	NULL
A.R	NULL
.	NULL

Saltiel	NULL
.	NULL

1995	NULL
.	NULL

Inhibition	NULL
of	NULL
MAP	NULL
kinase	NULL
kinase	NULL
blocks	NULL
the	NULL
differentiation	NULL
of	NULL
PC-12	NULL
cells	NULL
induced	NULL
by	NULL
nerve	NULL
growth	NULL
factor	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
:	NULL
13585-13588	NULL
.	NULL

Rechsteiner	NULL
,	NULL
M.	NULL
and	NULL
S.W	NULL
.	NULL

Rogers	NULL
.	NULL

1996	NULL
.	NULL

PEST	NULL
sequences	NULL
and	NULL
regulation	NULL
by	NULL
proteolysis	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

211	NULL
267-271	NULL
.	NULL

Rock	NULL
,	NULL
KL	NULL
.	NULL

,	NULL
C.	NULL
Gramm	NULL
,	NULL
L.	NULL
Rothstein	NULL
,	NULL
K.	NULL
Clark	NULL
,	NULL
R.	NULL
Stein	NULL
,	NULL
L.	NULL
Dick	NULL
,	NULL
D.	NULL
Hwang	NULL
,	NULL
and	NULL
A.L	NULL
.	NULL

Goldberg	NULL
.	NULL

1994	NULL
.	NULL

Inhibitors	NULL
of	NULL
the	NULL
proteasome	NULL
block	NULL
the	NULL
degradation	NULL
of	NULL
most	NULL
cell	NULL
proteins	NULL
and	NULL
the	NULL
generation	NULL
of	NULL
peptides	NULL
presented	NULL
on	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
.	NULL

Cell	NULL
78	NULL
:	NULL
761-771	NULL
.	NULL

Rogers	NULL
,	NULL
S.	NULL
,	NULL
R.	NULL
Wells	NULL
,	NULL
and	NULL
M.	NULL
Rechsteiner	NULL
.	NULL

1986	NULL
.	NULL

Amino	NULL
acid	NULL
sequences	NULL
common	NULL
to	NULL
rapidly	NULL
degraded	NULL
proteins	NULL
:	NULL
The	NULL
PEST	NULL
hypothesis	NULL
.	NULL

Science	NULL
234	NULL
:	NULL
364-368	NULL
.	NULL

Sakata	NULL
,	NULL
N.	NULL
,	NULL
H.R	NULL
.	NULL

Patel	NULL
,	NULL
N.	NULL
Terada	NULL
,	NULL
A.	NULL
Aruffo	NULL
,	NULL
G.L	NULL
.	NULL

Johnson	NULL
,	NULL
and	NULL
EW	NULL
.	NULL

Gelfand	NULL
.	NULL

1995	NULL
.	NULL

Selective	NULL
activation	NULL
of	NULL
c-Jun	NULL
kinase	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
by	NULL
CD40	NULL
on	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
:	NULL
30823-30828	NULL
.	NULL

Seyfert	NULL
,	NULL
V.L	NULL
.	NULL

,	NULL
D.	NULL
Allman	NULL
,	NULL
Y	NULL
.	NULL

He	NULL
,	NULL
and	NULL
LM	NULL
.	NULL

Staudt	NULL
.	NULL

1996	NULL
.	NULL

Transcriptional	NULL
repression	NULL
by	NULL
the	NULL
proto-oncogene	NULL
BCL-6	NULL
.	NULL

Oncogene	NULL
121	NULL
2331-2342	NULL
.	NULL

Sutherland	NULL
,	NULL
C.L	NULL
.	NULL

,	NULL
A.W	NULL
.	NULL

Heath	NULL
,	NULL
S.L	NULL
.	NULL

Pelech	NULL
,	NULL
P.R	NULL
.	NULL

Young	NULL
,	NULL
and	NULL
MR.	NULL
Gold	NULL
.	NULL

1996	NULL
.	NULL

Differential	NULL
activation	NULL
of	NULL
the	NULL
ERK	NULL
,	NULL
JNK	NULL
,	NULL
and	NULL
p38	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
by	NULL
CD40	NULL
and	NULL
the	NULL
B	NULL
cell	NULL
antigen	NULL
receptor	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

157	NULL
:	NULL
3381-3390	NULL
.	NULL

Tang	NULL
,	NULL
A.H.	NULL
,	NULL
TP	NULL
.	NULL

Neufeld	NULL
,	NULL
E.	NULL
Kwan	NULL
,	NULL
and	NULL
M.	NULL
Rubin	NULL
.	NULL

1997	NULL
.	NULL

PHYL	NULL
acts	NULL
to	NULL
down-regulate	NULL
TTK88	NULL
,	NULL
a	NULL
transcriptional	NULL
repressor	NULL
of	NULL
neuronal	NULL
cell	NULL
fates	NULL
,	NULL
by	NULL
a	NULL
SINA-dependent	NULL
mechanism	NULL
.	NULL

Cell	NULL
90	NULL
:	NULL
459-467	NULL
.	NULL

Tedder	NULL
,	NULL
TF	NULL
.	NULL

,	NULL
J.	NULL
Tuscano	NULL
,	NULL
S.	NULL
Sato	NULL
,	NULL
and	NULL
J.H	NULL
.	NULL

Kehrl	NULL
.	NULL

1997	NULL
.	NULL

CD22	NULL
,	NULL
a	NULL
B	NULL
lymphocyte-specific	NULL
adhesion	NULL
molecule	NULL
that	NULL
regulates	NULL
antigen	NULL
receptor	NULL
signaling	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

151	NULL
481-504	NULL
.	NULL

Vietor	NULL
,	NULL
I.	NULL
,	NULL
P.	NULL
Schwenger	NULL
,	NULL
W.	NULL
Li	NULL
,	NULL
J.	NULL
Schlessinger	NULL
,	NULL
and	NULL
J.	NULL
Vileek	NULL
.	NULL

1993	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor-induced	NULL
activation	NULL
and	NULL
increased	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
mitogen-activated	NULL
protein	NULL
(	NULL
MAP	NULL
)	NULL
kinase	NULL
in	NULL
human	NULL
fibroblasts	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
:	NULL
18994-18999	NULL
.	NULL

Xue	NULL
,	NULL
F.	NULL
and	NULL
L.	NULL
Cooley	NULL
.	NULL

1993	NULL
.	NULL

Kelch	NULL
encodes	NULL
a	NULL
component	NULL
of	NULL
in-tercellular	NULL
bridges	NULL
in	NULL
Drosophila	NULL
egg	NULL
chamber	NULL
.	NULL

Cell	NULL
72:68	NULL
1-693	NULL
.	NULL

Yan	NULL
,	NULL
M.	NULL
and	NULL
D.J	NULL
.	NULL

Templeton	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
of	NULL
2	NULL
serine	NULL
residues	NULL
of	NULL
MEK-1	NULL
that	NULL
are	NULL
differentially	NULL
phosphorylated	NULL
during	NULL
activation	NULL
by	NULL
raf	NULL
and	NULL
MEK	NULL
kinase	NULL
.	NULL

J	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
:	NULL
19067-19073	NULL
.	NULL

Ye	NULL
,	NULL
BH	NULL
.	NULL

,	NULL
G.	NULL
Cattoretti	NULL
,	NULL
Q.	NULL
Shen	NULL
,	NULL
J.	NULL
Zhang	NULL
,	NULL
N.	NULL
Hawe	NULL
,	NULL
R.	NULL
Waard	NULL
,	NULL
C.	NULL
Leung	NULL
,	NULL
M.	NULL
Nouri-Shirazi	NULL
,	NULL
A.	NULL
Orazi	NULL
,	NULL
R.S.K	NULL
.	NULL

Chaganti	NULL
,	NULL
P.	NULL
Rothman	NULL
,	NULL
A.M	NULL
.	NULL

Stall	NULL
,	NULL
P.P	NULL
.	NULL

Pandolfi	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
BCL-6	NULL
proto-oncogene	NULL
controls	NULL
germinal-centre	NULL
formation	NULL
and	NULL
Th2-type	NULL
inflammation	NULL
.	NULL

Nature	NULL
Genet	NULL
.	NULL

16	NULL
:	NULL
161-170	NULL
.	NULL

Ye	NULL
,	NULL
BH	NULL
.	NULL

,	NULL
S.	NULL
Chaganti	NULL
,	NULL
C.C	NULL
.	NULL

Chang	NULL
,	NULL
H.	NULL
Niu	NULL
,	NULL
P.	NULL
Corradini	NULL
,	NULL
R.S	NULL
.	NULL

Chaganti	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1995	NULL
.	NULL

Chromosomal	NULL
translocations	NULL
cause	NULL
deregulated	NULL
BCL6	NULL
expression	NULL
by	NULL
promoter	NULL
substitution	NULL
in	NULL
B	NULL
cell	NULL
lymphoma	NULL
.	NULL

EMBO	NULL
J	NULL
14	NULL
:	NULL
6209-6217	NULL
.	NULL

Ye	NULL
,	NULL
BH	NULL
.	NULL

,	NULL
F.	NULL
Lista	NULL
,	NULL
F.	NULL
Lo	NULL
Coco	NULL
,	NULL
D.M	NULL
.	NULL

Knowles	NULL
,	NULL
K.	NULL
Offit	NULL
,	NULL
R.S	NULL
.	NULL

Chaganti	NULL
,	NULL
and	NULL
R.	NULL
Dalla-Favera	NULL
.	NULL

1993	NULL
.	NULL

Alterations	NULL
of	NULL
a	NULL
zinc	NULL
finger-encoding	NULL
gene	NULL
,	NULL
BCL-6	NULL
,	NULL
in	NULL
diffuse	NULL
large-cell	NULL
lymphoma	NULL
.	NULL

Science	NULL
2621	NULL
747-150	NULL
.	NULL

Zhu	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Carroll	NULL
,	NULL
FR	NULL
.	NULL

Papa	NULL
,	NULL
M.	NULL
Hochstrasser	NULL
,	NULL
and	NULL
A.D.	NULL
D'Andrea	NULL
.	NULL

1996	NULL
.	NULL

DUB-1	NULL
,	NULL
a	NULL
deubiquitinating	NULL
enzyme	NULL
with	NULL
grow	NULL
th-suppressing	NULL
activity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

931	NULL
3275-3279	NULL
.	NULL

GENES	NULL
&	NULL
DEVELOPMENT	NULL
1961	NULL

